

**Saskatchewan Cancer Agency
Registry Data Dictionary**

Contents

PATIENT DEMOGRAPHICS	11
Date of Birth – MM/YYYY – All Years	11
Sex – Male, Female, etc. – All Years.....	11
Province – Current Province – All Years	11
Postal Code – First 3 characters only (current postal code) – All Years	11
CANCER CASE DETAILS (Initial Diagnosis)	11
Postal Code (at time case was diagnosed) – First 3 Characters only (at time of diagnosis) – All Years .	11
City (at time case was diagnosed) – City at the time of Diagnosis – All Years.....	11
Age at Diagnosis – Age at the time of Diagnosis – All Years.....	11
Gender at Diagnosis – Gender at the time of Diagnosis – 2018-Current	12
Date of Diagnosis – Date confirming the cancer Diagnosis – All Years.....	12
Primary Site, ICD-0 Topography English Description – i.e. Prostate – All Years.....	12
Histology ICD-0 Code – i.e. 8140 – All Years.....	12
Histology ICD-0 English Description – i.e. Adenocarcinoma NOS – All Years.....	12
Behaviour - /0 benign; /1 uncertain whether benign or malignant; /2 in situ; /3 malignant – All Years	12
Laterality – right, left, bilateral, midline, paired no info – All Years.....	13
Grade (2017 and prior-4 Grade System) I,1; II, 2; III, 3; IV, 4; 5; 6; 7; 8; 9.....	13
Grade – Grade Clinical; Grade Pathological; Grade Post Therapy - 2018-Current	14
Multiplicity Counter – 2008-2017 Counts the number of tumors (multiplicity) reported as a single primary.....	15
First Date of Diagnosis – Earliest proven or suspected date of diagnosis that prompts further investigations, whichever occurs first – All Years.....	15
First Method of Diagnosis – Initial report used to determine the first date field – All Years.....	15
Proven Method of Diagnosis – Proven method of Diagnosis – Path, Clinical, etc. – All Years	16
Diagnostic Confirmation – 2004-Current - Basis of most definitive diagnosis confirming cancer	16
Performance Scale (ECOG/Karnofsky) – Pt’s level of functioning in terms of their ability to care for themselves, daily activity and physical ability – All Years (as available)	16
Tumor Size Clinical – Size of a solid primary tumor before any treatment – 2018-Current	17
Tumor Size Pathological – Size of a solid primary tumor before any treatment – 2018-Current.....	17
Lymph Nodes Positive – Records the total number of regional lymph nodes that were removed and examined by the pathologist – 2018 - current.....	18

Lymph Nodes Exam - Records the total number of regional lymph nodes that were removed and examined by the pathologist – 2018 - Current18

Metastasis at Diagnosis-Bone - Identifies whether bone is an involved metastatic site – 2018 - Current19

Metastasis at Diagnosis-Brain – Identifies whether brain is an involved metastatic site – 2018 - Current19

Metastasis at Diagnosis-Liver – Identifies whether liver is an involved metastatic site – 2018-Current19

Metastasis at Diagnosis-Lung – Identifies whether lung is an involved metastatic site – 2018-Current19

Metastasis at Diagnosis-Other – Identifies whether other sites are an involved metastatic site – 2018 - Current20

Metastasis at Diagnosis-Distant Node(s) – Identifies whether distant lymph node is an involved metastatic site – 2018 - Current.....20

Lymph Vascular Invasion – 0=lymphovascular invasion states as not present; 1=lymphovascular invasion present/identified; 2=lymphatic and small vessel invasion only (L); 3=venous (large vessel) invasion only (V); 4=BOTH lymphatic and small vessel AND venous (large vessel) invasion; 8=N/A; 9=unknown – 2010-Current (2,3,4 – new for2018-Current).....20

TNM Clinical Classification-(T) Tumor – Describes the size of the tumor and any spread of cancer into nearby tissue clinically before cancer directed treatment – 2018 - Current21

TNM Clinical T Suffix – Identifies multiple or solitary tumors – 2018 - Current21

TNM Clinical Classification-(N) Lymph Nodes – Describes spread of cancer to nearby lymph nodes clinically before the start of any therapy – 2018 - Current21

TNM Clinical N Suffix – Identifies if a sentinel node procedure done, fine needle aspiration or core biopsy done – 2018 - Current21

TNM Clinical Classification-(M) Metastasis – Describes if there are distant metastases clinically before the start of any therapy – 2018 - Current.....21

TNM Clinical Stage Group – Identified the extant of disease based on the T, N, and M category variables known before the start of any therapy – 2018 - Current.....21

TNM Pathological Classification-(T) Tumor – Described the size of the tumor and any spread of cancer into nearby tissue pathologically following the completion of surgery – 2018 - Current22

TNM Path T Suffix – Identifies multiple or solitary tumors – 2018 - Current.....22

TNM Pathological Classification-(N) Lymph Nodes – Describes spread of cancer to nearby lymph nodes pathologically following the completion of surgery – 2018 - Current22

TNM Path N Suffix – Identifies if a sentinel node procedure done, fine needle aspiration or core biopsy bone – 2018 - Current22

TNM Pathological Classification-(M) Metastasis – Describes in there are distant metastasis pathologically following the completion of surgery – 2018 - Current22

TNM Pathologic Stage Group – Identifies the extent of disease based on the Pathologic, T, N and M categories – 2018 - Current.....	22
TNM Post Therapy Classification-(T) Tumor – Describes the size of the tumor and any spread of cancer into nearby tissue pathologically following the completion of neoadjuvant treatment – 2018-Current	23
TNM Post Therapy T Suffix – Identifies multiple or solitary tumors – 2018-Current	23
Post Therapy Classification-(N) Lymph Nodes – Describes spread of cancer to nearby lymph nodes following the completion of neoadjuvant treatment – 2018-Current.....	23
TNM Post Therapy N Suffix – Identifies if a sentinel node procedure done, fine needle aspiration or core biopsy done – 2018-Current.....	23
TNM Post Therapy Classification-(M) Metastasis– M category for postneoadjuvant therapy staging remains the same as that assigned in the clinical stage before initiation of neoadjuvant therapy, cM or pM – 2018-Current.....	23
TNM Post Therapy Stage Group – Identifies the remaining extent of disease based on the T and N following the completion of neoadjuvant therapy and planned postneoadjuvant therapy surgical resection, and the M status defined during the diagnostic workup – 2018-Current	23
Site Specific Data Items (SSDIs) (Dependent on Cancer Site and Diagnosis Year – Colorectal – 2018; Breast, Prostate, Lung – 2019; Hematological, Brain, Thyroid – 2020; Default/Unknown values are entered for all other sites) – 2018-Current.....	24
SSDIs – Dependent on Site – 2018-Curent	24
Biopsy Code – Biopsy at time of diagnosis (ICD-9-CM) – All Years	24
Surgery Code – Surgery at time of diagnosis (ICD-9-CM) – All Years	24
Definitive Surgery Code – The most extensive surgery performed on the patient during the final diagnosis timeframe (ICD-9-CM) – 2018-Current.....	24
Procedure Code – Procedure at time of diagnosis (ICD-9-CM)	24
Surgical Margin– 0-no residual tumor; 1-residual tumor NOS; 9-unknown or not applicable – 2018-Current.....	25
Date of Biopsy – MM/DD/YYYY – 2018-Current.....	25
Date of Surgery – MM/DD/YYYY – Up to and including 2010 (99/99/9999); Date from 2011-Current .	25
Date of Definitive Surgery – MM/DD/YYYY – 2018-Current.....	25
Date of Procedure – MM/DD/YYYY – 2018-Current	25
Start Date of Radiation Therapy – MM/DD/YYYY – Up to and including 2009 (99/99/9999); Date from 2010-Current.....	25
Start Date of Chemotherapy – MM/DD/YYYY – Up to and including 2009 (99/99/9999); Date from 2010-Current.....	25

Start Date of Hormone Therapy – MM/DD/YYYY – Up to and including 2009 (99/99/9999); Date from 2010-Current	26
Start Date of Immunotherapy – MM/DD/YYYY – Up to and including 2009 (99/99/9999); Date from 2010-Current	26
Start Date of Other Treatment/Rx – MM/DD/YYYY – Up to and including 2009 (99/99/9999); Date from 2010-Current	26
Date of Transplant (Hematopoietic Case) – MM/DD/YYYY – Up to and including 2010 (99/99/9999); Date from 2011-Current	26
Disease/Tumor Status – Disease, disease free or unknown – All Years.....	26
Disease/Tumor Status Date – MM/DD/YYYY – All Years.....	26
Date of Metastasis – MM/DD/YYYY – All Years.....	27
Site of Metastasis at Diagnosis, ICD-0 Topography Code – i.e. C419 – All Years.....	27
Site of Metastasis at Diagnosis, English Description – Bone, NOS – All Years.....	27
Metastasis Identified –2010-Current Clinical, Path, Radiological.....	27
Metastasis Eliminated –2010-Current How the metastasis/metastases were treated to eliminate the metastasis.....	27
Complications at Diagnosis – Complications that alter planned treatment – All Years.....	28
Date of Complication – MM/DD/YYYY – All Years	28
Consequence of Complication – Consequence/reason that resulted from the complication - R-refused; D-delayed; S-stopped; C-changed – 2019-Current or Not Applicable	28
COLLABORATIVE STAGE (CS) CLINICAL-PATHOLOGICAL STAGING SYSTEM – Years available for all CS Data Elements: Breast and Colorectal-2005; Lung-2006; Prostate and Head&Neck-2007; Gynecological, Melanoma and Hematopoietic-2008; Urinary and Upper GI-2009; 2017-All Sites-2010	29
CS Tumor Size – Largest dimension or diameter of the primary tumor – See Table for Years Available for CS	29
CS Extension – Identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs – See Table for Years Available for CS	29
CS Tumor Size/Ext Eval – How the most extensive tumor was established as well as whether the patient received preoperative treatment - See Table for Years Available for CS	30
CS Lymph Nodes – Identifies the regional lymph nodes involved with cancer at the time of diagnosis – See Table for Years Available for CS.....	30
CS Lymph Nodes Evaluation – How the most extensive tumor was established as well as whether the patient received preoperative treatment – See Table for Years Available for CS.....	31
Regional Lymph Nodes Positive – Number of regional lymph nodes examined by the pathologist and found to contain metastases – See Table for Years Available for CS	32

Regional Lymph Nodes Examined – Total number of regional lymph nodes that were removed and examined by the pathologist – See Table for Years Available for CS	32
CS Metastasis Diagnosis – Distant site(s) of metastatic involvement at time of diagnosis – See Table for Years Available for CS.....	32
CS Metastasis Evaluation – How the most extensive tumor was established as well as whether the patient received preoperative treatment – See Table for Years Available for CS.....	33
CS Metastasis at Diagnosis – Bone – This field is a companion to CS Mets at Dx that identifies whether bone is an involved metastatic site – 2010-2017	33
CS Metastasis at Diagnosis – Brain – This field is a companion to CS Mets at Dx that identifies whether brain is an involved metastatic site – 2010-2017	34
CS Metastasis at Diagnosis – Liver – This field is a companion to CS Mets at Dx that identifies whether liver is an involved metastatic site – 2010-2017	34
CS Metastasis at Diagnosis – Lung – This field is a companion to CS Mets at Dx that identifies whether lung is an involved metastatic site – 2010-2017	34
CS SITE SPECIFIC FACTORS (SSF) – SSF1-SSF25; All SSF’s differ based on primary cancer site. (See page 45 for inclusive list off all SSF’s SCA collects for each primary site); Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival	34
CS – SSF1 – Dependent on Site	35
CS – SSF2 – Dependent on Site	35
CS – SSF3 – Dependent on Site	35
CS – SSF4 – Dependent on Site	35
CS – SSF5 – Dependent on Site	36
CS – SSF6 – Dependent on Site	36
CS – SSF7 – Dependent on Site	36
CS – SSF8 – Dependent on Site	36
CS – SSF9 – Dependent on Site	36
CS – SSF10 – Dependent on Site	36
CS – SSF11 – Dependent on Site	36
CS – SSF12 – Dependent on Site	36
CS – SSF13 – Dependent on Site	37
CS – SSF14 – Dependent on Site	37
CS – SSF15 – Dependent on Site	37
CS – SSF16 – Dependent on Site	37
CS – SSF17 – Dependent on Site	37





CS – SSF18 – Dependent on Site	37
CS – SSF19 – Dependent on Site	37
CS – SSF20 – Dependent on Site	37
CS – SSF21 – Dependent on Site	38
CS – SSF22 – Dependent on Site	38
CS – SSF23 – Dependent on Site	38
CS – SSF24 – Dependent on Site	38
CS – SSF25 – Dependent on Site	38
Overall TNM Stage Grp – Using the TNM descriptions to assign an overall stage from 0 to 4 - Stages I to IV – Up to and incl. 2009 as available; 2010-2017	38
T-Value - TNM Stage – Describes the size of the tumor and any spread of cancer into nearby tissue – Up to and incl. 2009 as available; 2010-2017	39
N-Value – TNM Stage – Describes spread of cancer to nearby lymph nodes – Up to and incl. 2009 as available; 2010-2017	39
M-Value – TNM Stage – Describes if there are distant metastases – Up to and incl. 2009 as available; 2010-2017	39
REVIEW INFORMATION/CASE SUMMARY (details occurring after initial diagnosis & treatment)	39
Source Document Type (2010-Current) – Report used to code a review – 2010-Current	39
Source Document Date – Date of report used to code a review – All Years	40
Diagnostic Imaging –2010-Current Type of Imaging Report	40
Disease/Tumor Status – Disease, disease free or unknown – All Years	40
Disease/Tumor Status Date – MM/DD/YYYY – All Years	41
Recurrence Identified – 2010-Current Clinical, Path, Radiological	41
Recurrence Eliminated– 2010-Current – How the recurrence was treated to eliminate the recurrence	41
Date of Recurrence – MM/DD/YYYY – All Years	42
Site of Metastasis – Topography and English description of site of metastasis/metastases – All Years	42
Date of Metastasis – MM/DD/YYYY – All Years	42
Metastasis Identified – 2010-Current Clinical, Path, Radiological	42
Metastasis Eliminated – 2010-Current How the metastasis/metastases were treated to eliminate the mets	42
Biopsy at Review – Biopsy at time of review (ICD-9-CM) – All Years	43

Date of Biopsy at Review – MM/DD/YYYY – Up to and incl. 2010 (99/99/9999); Date from 2011-Current	43
Biopsy Code(s) at Review – Biopsy code in ICD-9-CM – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	43
Surgery at Review – Surgery at time of review (ICD-9-CM) – All Years.....	43
Date of Surgery at Review – MM/DD/YYYY – Up to and incl. 2010 (99/99/9999); Date from 2011-Current	43
Surgery Code(s) at Review – Surgery codes in ICD-9-CM – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	43
Procedure at Review – Procedure at time of review (ICD-9-CM) – 2010-Current	43
Date of Procedure at Review – MM/DD/YYYY – Up to and incl. 2010 (99/99/9999); Date from 2011-Current	43
Procedure Code(s) at Review – Procedure codes in ICD-9-CM – Up to and incl. 2010 (99/99/9999); Date from 2011-Current	44
Chemo at Review – Selected if coding chemo information – All Years.....	44
Start Date of Chemo – MM/DD/YYYY – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	44
End Date of Chemo – 2010-Current – MM/DD/YYYY	44
Radiation Therapy at Review – Selected if coding radiation information – All Years.....	44
Start Date of Radiation – MM/DD/YYYY – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	44
End Date of Radiation – 2010-Current – MM/DD/YYYY	44
Hormone at Review – Selected if coding hormone information – All Years.....	44
Start Date of Hormone – MM/DD/YYYY – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	45
End Date of Hormone -2010-Current – MM/DD/YYYY	45
Immuno Therapy at Review – Selected if coding immuno information – All Years	45
Start Date of Immuno Therapy – MM/DD/YYYY – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	45
End Date of Immuno Therapy – 2010-Current – MM/DD/YYYY.....	45
Transplant at Review – Selected if coding transplant information – 2010-Current.....	45
Start Date of Transplant – MM/DD/YYYY – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	45
Other Treatment at Review – Selected if coding other treatment information – All Years.....	45

Start Date of Other Treatment – MM/DD/YYYY – Up to and incl. 2009 (99/99/9999); Date from 2010-Current	46
End Date of Other Treatment – 2010-Current – MM/DD/YYYY	46
Complication at Review – Complications that alter planned treatment – All Years.....	46
Date of Complication – MM/DD/YYYY – All Years	46
Consequence of Complication – 2019-Current or Not Applicable – Consequence/reason that resulted from the complication; R-refused, D-delayed, S-stopped, C-changed	47
Date of Last Follow-up – Date of last Follow up documented (date of last source doc on last coded review), MM/DD/YYYY – All Years.....	47
DEATH INFORMATION.....	47
Date of Death – MM/YYYY – All Years.....	47
Underlying Cause of Death (UCOD) (Primary Cause of Death) – ICD-10 or ICD-9 – All Years	47
Multiple Cause of Death (Secondary Cause of Death) – ICD-10 or ICD-9 – All Years.....	47
Place of Death – City/Town where patient died – All Years	47
Collaborative Stage (CS) Site Specific Factors (SSF) SCA Collects	48
Collaborative Stage (CS) Site Specific Factors (SSF) SCA Collects – Dependent on Site – 2007-2017	48
Site Specific Data Items (SSDI's) SCA Collects.....	74
Site Specific Data Items (SSDI) SCA Collects -2018-Current.....	74

DATA DEFINITIONS

NOTE:

-  Date format is MM/DD/YYYY – when 9's are included in partial or all date values, that portion of the date is unknown. I.e.: 01/99/2000 would mean Jan of 2000 but unknown day.
-  Cancer Registry began collecting dates for radiation, chemotherapy, hormone, immunotherapy and other in 2010. Prior to 2010 all dates will be 99/99/9999 (unknown date) and Registry began collecting dates for surgery and transplant in 2011. Prior to 2011, all dates will be 99/99/9999 (unknown date).
-  Some data elements are not mandatory and are collected as available.
-  Historical Data is unknown data. When the new Registry database was implemented, some data elements were not collected in as much detail as they are today.

PATIENT DEMOGRAPHICS

Date of Birth

This field collects patient's date of birth. Day of birth will not be released as day has the potential to identify a patient.

MM/YYYY format will be released.

Sex

Sex of the patient

1-Male

2-Female

3-Other

4-Transsexual

9-Not Stated

Province

Province where the patient currently resides, i.e. SK, AB

Postal Code

Postal code of where the patient currently resides. First 3 characters only will be released

CANCER CASE DETAILS (Initial Diagnosis)

Postal Code (at time case was diagnosed)

The postal code for where the patient resided at the time of the cancer diagnosis

First 3 characters only will be released

City (at time case was diagnosed)

The city where the patient resided at the time of the cancer diagnosis

Age at Diagnosis

The age at which the patient was diagnosed

Gender at Diagnosis

The gender at which patient was diagnosed

Date of Diagnosis

The first cytology or pathology date that proves the diagnosis of cancer. In the absence of cytology/pathology, use the date of the first report that confirms cancer. Priority of report used to collect Date of Diagnosis is determined by CCR.

MM/DD/YYYY

Primary Site, ICD-0 Topography Code & Primary Site English Description

The four-digit alpha-numeric code for the cancer site in ICD-O (International Classification of Diseases for Oncology). Topography describes the anatomical site of origin (or organ system) of the tumor.

C000 to C809

Primary Site, ICD-0 Topography English Description

The English description of the primary site topography code.

Histology ICD-0 Code

The morphology/histology code for the cancer site. Histology describes the cell type of the tumor, whereas Morphology describes the cell type of the tumor together with the behaviour of the tumor.

Histology ICD-0 English Description

The English description of the morphology/histology code.

Behaviour

The behaviour of a tumor is the way it acts within the body. It is the fifth digit of the ICDO-Morphology code.

-/0 benign

-/1 uncertain whether benign or malignant (borderline malignancy, low malignant potential or uncertain malignant potential)

- /2 insitu (intraepithelial, noninfiltrating or noninvasive)
- /3 malignant

Laterality

Identifies the side of a paired organ or the side of the body on which the reportable tumor originated. Some organs, like prostate, are not considered to be paired organs. This applies to the primary site only.

- 0-Not Paired
- 1-Right
- 2-Left
- 3-One Side unspecified
- 4- Bilateral Simultaneous
- 5-Mid Line
- 9-Paired no information
- X-Historical

Grade (2017 and prior-4 Grade System)

Pathologic testing determines the grade, or degree of differentiation, of the tumor. For cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). Well differentiated tumor cells closely resemble the tissue from the organ of origin. Poorly differentiated and undifferentiated tumor cells are disorganized and abnormal looking; they bear little or no resemblance to the tissue from the organ of origin. These similarities/differences may be based on pattern (architecture), cytology, or nuclear features; or a combination of these elements depending upon the grading system that is used. The information from this data item is useful for determining prognosis and treatment.

Pathologists describe the tumor grade using three systems or formats:

1. Two levels of similarity; also called a two-grade system (may be used for colon, for example)
2. Three levels of similarity; also called a three-grade system (code according to “coding grade for solid tumors”).
 - a. Grade I, well
 - b. Grade II, moderately
 - c. Grade III, poorly (undifferentiated is usually separated from this system, since poorly bears some similarity to the host tissue, while undifferentiated has none. e.g. Undifferentiated carcinoma.
3. Four levels of similarity; also called a four-grade system. The four-grade system

describes the tumor as:

- a. Grade I; also called well differentiated
- b. Grade II; also called moderately differentiated
- c. Grade III; also called poorly differentiated
- d. Grade IV; also called undifferentiated or anaplastic

4. Hematology cases use Cell indicator codes to describe the lineage or phenotype of the cell that became malignant. Cell indicator codes apply to hematopoietic and lymphoid neoplasms only (ICD-O-3-Histology range 9590-9992) and for these diagnoses cell indicator takes precedence over grade/differentiation.

- a. Code 5; T-cell; T-precursor
- b. Code 6; B-Cell; Pre-B; B-precursor
- c. Code 7; Null cell; Non T-non B
- d. Code 8; NK cell (natural killer cell)

5. Code 9; all systems use code 9 to indicate Grade/differentiations unknown, not stated, or not applicable

Grade – Grade Clinical; Grade Pathological; Grade Post Therapy - 2018-Current

Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers.

For solid tumors diagnosed 2018 and forward, grade will be collected in three different data items. The codes and coding instructions are dependent on the type of cancer.

Grade Clinical-This data item records the grade of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant).

Grade Pathological-This data item records the grade of a solid primary tumor that has been resected and for which no neoadjuvant therapy was administered. This may include the grade from the clinical workup. Record the highest grade documented from any microscopic specimen of the primary site whether from the clinical workup or the surgical resection.

Grade Post Therapy-This data item records the grade of a solid primary tumor that has been resected following neoadjuvant therapy. Record the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy.

Beginning with cases diagnosed in 2018, the definition of grade has been expanded, and classification of grade now varies by tumor site and/or histology. The grading system for a cancer type may have 2, 3, or 4 grades. No longer will all grades be converted to a four-grade system.

Template for a Cancer-Specific Grade Table :

- 1-Site-specific grade system category
- 2-Site-specific grade system category
- 3-Site-specific grade system category
- 4-Site-specific grade system category
- 5-Site-specific grade system category
- 8-Not applicable (Some Hematopoietic neoplasms only)
- 9-Grade cannot be assessed; unknown
- A-Well differentiated
- B-Moderately differentiated
- C-Poorly differentiated
- D-Un differentiated and anaplastic
- E-Site-specific grade system category
- H-High grade
- L-Low grade
- M- Site-specific grade system category
- S- Site-specific grade system category
- Blank-(Post therapy only)

Multiplicity Counter – 2008-2017

Counts the number of tumors (multiplicity) that are reported as a single primary

01, 02, 03, 04, etc.

First Date of Diagnosis

Earliest proven or suspected date of diagnosis that prompts further investigations, whichever occurs first

MM/DD/YYYY

First Method of Diagnosis

Initial report used to determine the first date of diagnosis

- 00-Unknown/not stated
- 01-Pathology
- 02-Cytology
- 03-Radiology
- 04-Exploratory Surgery (no biopsy)
- 05-Clinical
- 06-Autopsy
- 07-Mammogram

- 08-Biochemical (bloodwork)
- 09-Death Certificate Only (DCO)
- 99-Other

Proven Method of Diagnosis

Final method used to determine the patient's diagnosis

- 00-Unknown/not stated
- 01-Pathology
- 02-Cytology
- 03-Radiology
- 04-Exploratory surgery (no biopsy)
- 05-Clinical
- 06-Autopsy
- 07-Mammography
- 08-Biochemical (bloodwork)
- 09-Death Certificate Only (DCO)
- 99-Other

Diagnostic Confirmation – 2004-Current -

Code for the best method of diagnostic confirmation of the cancer being reported at any time in the patient's history

- 1-Positive Histology
- 2-Cytology
- 3-Positive Histology + positive immunophenotyping AND/OR positive genetic studies (used only for hematopoietic and lymphoid neoplasms M-9590/3-9992/3) was adopted for use effective with 2010 diagnoses)
- 5-Positive Lab/Marker
- 6-Visualization
- 7-Radiography Only
- 8-Clinical Only
- 9-Unknown whether or not microscopically confirmed; death certificate only

Performance Scale (ECOG/Karnofsky)

Patient's level of functioning in terms of their ability of care for themselves, daily activity and physical ability.

ECOG/ Karnofsky

- 0/4-Fully Active, able to carry out all predisease activities without restriction (Karnofsky

90-100)

1/4-Restricted in physically strenuous activity but ambulatory and able to carry work of a light or sedentary nature. For example, light housework, office work (Karnofsky 70-80)

2/4- Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours Karnofsky (50-60)

3/4-Capable of only limited self-care, confined to bed or chair 50% or more of waking hours (Karnofsky 30-40)

4/4-Completely disabled. Cannot carry on self-care. Totally confined to bed (Karnofsky 10-20)

5-Death (Karnofsky 0)

Tumor Size Clinical

Records the size of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant). Clinical classification is composed of diagnostic workup prior to first treatment, including physical examination, imaging, pathological findings (gross and microscopic measurements), and surgical exploration without resection. Tumor size is recorded in millimeters.

000-No mass/tumor found

001-1mm or described as less than 1mm

002-988-Exact size in mm

989-989 millimeters or larger

990-Microscopic focus or foci only and no size of focus is given

998-Alternate descriptions of tumor size for specific sites:

Familial/multiple polyposis-Rectosigmoid and rectum (C19.9, C20.9), Colon (C18.0, C18.2-C18.9)

If no size is documented:

Circumferential-Esophagus (C15.0-C15.5, C15.8-C15.9)

Diffuse; widespread: three-fourths or more; linitis plastica-Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)

Diffuse, entire lung or NOS-Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)

Diffuse-Breast (C50.0-C50.6, C50.8-C50.9)

999- Unknown; size not stated, Not documented in patient record, Size of tumor cannot be assessed, The only measurement(s) describes pieces or chips or Not applicable

Tumor Size Pathological

Records the size of a solid primary tumor that has been resected. Pathologic classification includes operative and pathological findings of the resected specimens. Tumor size is recorded in millimeters.

- 000-No mass/tumor found
- 001-1mm or described as less than 1mm
- 002-988-Exact size in mm
- 989-989 millimeters or larger
- 990-Microscopic focus or foci only and no size of focus is given
- 998-Alternate descriptions of tumor size for specific sites:
 - Familial/multiple polyposis-Rectosigmoid and rectum (C19.9, C20.9), Colon (C18.0, C18.2-C18.9)
 - If no size is documented:
 - Circumferential-Esophagus (C15.0-C15.5, C15.8-C15.9)
 - Diffuse; widespread: three-fourths or more; linitis plastica-Stomach and Esophagus GE Junction (C16.0-C16.6, C16.8-C16.9)
 - Diffuse, entire lung or NOS-Lung and main stem bronchus (C34.0-C34.3, C34.8-C34.9)
 - Diffuse-Breast (C50.0-C50.6, C50.8-C50.9)
- 999- Unknown; size not stated, Not documented in patient record, Size of tumor cannot be assessed, The only measurement(s) describes pieces or chips or Not applicable

Lymph Nodes Positive

Regional Nodes Positive records the exact number of regional nodes examined by the pathologist and found to contain metastasis.

- 00-All nodes examined are negative
- 01-89-1-89 nodes are positive
- 90-90 or more nodes are positive
- 95-Positive Aspiration OR core biopsy of lymph node(s) was performed
- 97-Positive nodes are documented, but the number is unspecified
- 98- No nodes were examined
- 99- It is unknown whether nodes are positive; not applicable; not stated in patient record

Lymph Nodes Exam

Regional Nodes Examined records the total number of regional lymph nodes that were removed and examined by the pathologist.

- 00-No nodes were examined
- 01-89-1-89 nodes are positive
- 90-90 or more nodes are positive
- 95-No regional nodes were removed, but aspiration OR core biopsy regional nodes was performed
- 96- Regional lymph node removal was documented as a sampling, and the number of

nodes is unknown/not stated

97- Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated

98- Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown

99- It is unknown whether nodes are examined; not stated in patient record

Metastasis at Diagnosis-Bone

Identifies whether bone is an involved metastatic site

0-None: no bone metastases

1-Yes: distant bone metastases

8-Not applicable

9-Unknown whether bone is an involved metastatic site, not documented in patient record

Metastasis at Diagnosis-Brain

Identifies whether brain is an involved metastatic site

0-None: no brain metastases

1-Yes: distant brain metastases

8-Not applicable

9-Unknown whether brain is an involved metastatic site, not documented in patient record

Metastasis at Diagnosis-Liver

Identifies whether liver is an involved metastatic site

0-None: no liver metastases

1-Yes: distant liver metastases

8-Not applicable

9-Unknown whether liver is an involved metastatic site, not documented in patient record

Metastasis at Diagnosis-Lung

Identifies whether lung is an involved metastatic site

- 0-None: no lung metastases
- 1-Yes: distant lung metastases
- 8-Not applicable

9-Unknown whether lung is an involved metastatic site, not documented in patient record

Metastasis at Diagnosis-Other

Identifies any type of distant involvement not captured in the Mets at Diagnosis-Bone, Mets at Diagnosis-Brain, Mets at Diagnosis-Liver, Mets at Diagnosis-Lung, and Mets at Diagnosis-Distant Lymph Nodes fields. It includes involvement of other specific sites and more generalized metastases such as carcinomatosis. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, malignant pleural effusion, peritoneum, and skin.

- 0-None: no other metastases
- 1-Yes: distant metastases in known site(s) other than bone, brain, liver, lung, or distant lymph nodes. Note: includes bone marrow involvement for lymphomas
- 2-Generalized metastasis such as carcinomatosis
- 8-Not applicable
- 9- Unknown whether any other metastatic site or generalized metastases, Not documented in patient record

Metastasis at Diagnosis-Distant Node(s)

Identifies whether distant lymph node is an involved metastatic site.

- 0-None: no distant lymph node metastases
- 1-Yes: distant lymph node metastases
- 8-Not applicable
- 9-Unknown whether distant lymph node is an involved metastatic site, not documented in patient record

Lymph Vascular Invasion

Indicates whether lymphatic duct or blood vessel (LVI) is identified in the pathology report. This is useful for prognosis.

Note: 2, 3 & 4 are new for 2018-current

- 0-Lymphovascular Invasion stated as Not Present
- 1-Lymph-vascular Invasion Present/Identified
- 2-Lymphatic and small vessel invasion only (L)
- 3-Venous (large vessel) invasion only (V)
- 4-BOTH lymphatic and small vessel AND venous (large vessel) invasion

8-Not applicable

9- Unknown/Indeterminate/not mentioned in path report

TNM Clinical Classification-(T) Tumor

Identifies the site-specific code evaluating the primary tumor clinically (T) and reflects the tumor size and/or extension as recorded. Clinical stage is assigned before any cancer-directed treatment and should not be changed based on subsequent information.

TNM Clinical T Suffix

(m)-Multiple synchronous tumors OR multifocal tumor (thyroid differentiated and anaplastic only)

(s)-Solitary tumor (thyroid differentiated and anaplastic only)

Blank- No information available, not recorded

TNM Clinical Classification-(N) Lymph Nodes

Identifies the absence or presence of clinical regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known before the start of any therapy. Clinical stage is assigned before any cancer-directed treatment and should not be changed based on subsequent information.

TNM Clinical N Suffix

(sn)-Sentinel node procedure without resection of nodal basin

(f)-Fine needle aspiration or core needle biopsy without resection of the nodal basin

Blank-No information available, not recorded

TNM Clinical Classification-(M) Metastasis

Identifies the presence or absence of clinical distant metastasis (M) before the start of any therapy. Clinical stage is assigned before any cancer-directed treatment and should not be changed based on subsequent information.

TNM Clinical Stage Group

Identifies the anatomic extent of disease based on the T, N and M category variables known before the start of any therapy, and provides detailed site-specific values for the Clinical Stage Group

TNM Pathological Classification-(T) Tumor

Evaluates the primary tumor (T) and reflects the known tumor size and/or extension of the tumor following the completion of surgical therapy. Pathological stage uses all data for clinical staging, and the evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination.

TNM Path T Suffix

(m)-Multiple synchronous tumors OR multifocal tumor (thyroid differentiated and anaplastic only)

(s)-Solitary tumor (thyroid differentiated and anaplastic only)

Blank- No information available, not recorded

TNM Pathological Classification-(N) Lymph Nodes

Identifies the absence or presence of pathological regional lymph node (N) metastasis and describes the known extent of regional lymph node metastasis of the tumor following the completion of surgical therapy. Pathological stage uses all data for clinical staging, and the evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination.

TNM Path N Suffix

(sn)-Sentinel node procedure without resection of nodal basin

(f)-Fine needle aspiration or core needle biopsy without resection of the nodal basin

Blank-No information available, not recorded

TNM Pathological Classification-(M) Metastasis

Identifies the known presence or absence of pathological distant metastasis (M) of the tumor following the completion of surgical therapy. Pathological stage uses all data for clinical staging, and the evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination.

TNM Pathologic Stage Group

Identifies the anatomic extent of disease based on the Pathologic T, N and M elements as recorded in the TNM Pathologic T, N and M variables.

TNM Post Therapy Classification-(T)

Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection.

TNM Post Therapy T Suffix

(m)-Multiple synchronous tumors OR multifocal tumor (thyroid differentiated and anaplastic only)

(s)-Solitary tumor (thyroid differentiated and anaplastic only)

Blank- No information available, not recorded

Post Therapy Classification-(N) Lymph Nodes

Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of lymph node metastasis of the tumor known known following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection.

TNM Post Therapy N Suffix

(sn)-Sentinel node procedure without resection of nodal basin

(f)-Fine needle aspiration or core needle biopsy without resection of the nodal basin

Blank-No information available, not recorded

TNM Post Therapy Classification-(M) Metastasis

M category for postneoadjuvant therapy staging remains the same as that assigned in the clinical stage before initiation of neoadjuvant therapy, cM or pM.

TNM Post Therapy Stage Group

Identifies the remaining anatomic extent of disease based on the T and N following the completion of neoadjuvant therapy (satisfying the definition for that disease site) and planned postneoadjuvant therapy surgical resection, and the M status defined during the diagnostic workup.

Site Specific Data Items (SSDIs)

SSDIs

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival.

Dependent on Cancer Site and Diagnosis Year (Default/Unknown values are entered for all other sites):

2018-Colorectal

2019-Breast, Prostate and Lung

2020-Hematological, Brain and Thyroid

(See page 68 for inclusive list off all SSDI's SCA collects for each site)

Biopsy Code

ICD-9-CM procedure code a biopsy performed at the time of diagnosis.

Numerical code

Surgery Code

ICD-9-CM procedure code for the surgery/surgeries performed at the time of diagnosis.

Numerical code

Definitive Surgery Code

ICD-9-CM procedure code for the most extensive surgery performed on the patient during the initial diagnosis timeframe, whether or not there was tumor present in the resultant pathology and whether or not it is considered the most extensive surgery that is possible to be performed for that particular site.

Procedure Code

ICD-9-CM procedure code for the procedures/scopes performed.

Numerical code

Surgical Margin

Surgical Margins of the Primary Site describes the final status of the surgical margins after resection of the primary tumor during Definitive Surgery.

- 0-No residual tumor
- 1-Residual tumor
- 9-Unknown or not applicable

Date of Biopsy

Date of biopsy performed

MM/DD/YYYY

Date of Surgery

Date of surgery that was performed

MM/DD/YYYY

Date of Definitive Surgery

Date of definitive surgery

MM/DD/YYYY

Date of Procedure

Date of the procedure

MM/DD/YYYY

Start Date of Radiation Therapy

Start date of radiation therapy

MM/DD/YYYY

Start Date of Chemotherapy

Start date of chemotherapy regime

MM/DD/YYYY

Start Date of Hormone Therapy

Start date of hormone therapy

MM/DD/YYYY

Start Date of Immunotherapy

Start date of immunotherapy

MM/DD/YYYY

Start Date of Other Treatment/Rx

Start date of other therapies that are cancer related therapies but not categorized into RT, chemo, hormone or immunotherapy

MM/DD/YYYY

Date of Transplant

Start date of transplant for hematopoietic cases only

MM/DD/YYYY

Disease/Tumor Status

Indicates the patient disease/tumor status at time of initial diagnosis

- 1-Free (NED)-No evidence of disease
- 2-Not free this tumor
- 9-Unknown tumor status

Disease/Tumor Status Date

Date of patients disease/tumor status

MM/DD/YYYY

Date of Metastasis

Date the metastasis was diagnosed

MM/DD/YYYY

Site of Metastasis at Diagnosis, ICD-0 Topography Code

The four-digit code for the metastatic cancer site in ICD-O (International Classification of Diseases for Oncology)

C000 to C809

Site of Metastasis at Diagnosis, English Description

The English description of the topography metastatic site code

I.e. – bone, NOS

Metastasis Identified –2010-Current

How the metastasis was identified

- C-Clinical
- P-Pathological
- R-Radiological
- H-Historical Data

Metastasis Eliminated –2010-Current

How the metastasis were treated to eliminate the metastasis.

- C-Chemo
- I-Immuno
- M-Multiple
- O-Other
- R-Radiation
- S-Surgery
- T-Transplant
- U-Unknown
- H-Historical data

Complications at Diagnosis

Complication is a physical condition/disease affecting the patient's status that delays, alters or prevents the normal course of treatment.

V64.1-Contraindication. Any health condition preventing, stopping or delaying treatment, including disease progression

V64.2-Patient refusal or discontinuation of recommended treatment or intentional non-compliance

V64.3-Other reasons. Any other factors that delay the treatment such as winter storm, family member is sick, planned holidays, seeding and harvesting

995.2-Unusual adverse side effect of drug. Usually results in a change or drug regime

990-Radiation sickness. Adverse effect from Radiation that stops treatment

459.2-Superior Vena Cava Obstruction (SVC)

336.9-Cord Compression (CC)

996.8-Graft vs Host Disease (GVHD)

New for 2020:

U07.1-COVID-19 virus identified. Patients identified with having COVID-19 virus and therefore could not proceed with planned treatment.

U07.2-COVID-19 complication due to pandemic. Patients who do not have the virus but whose treatment was affected as a result of scheduling delays or other issues related to the pandemic. Code is also used for patients whose diagnosis, screening appointments, or initial physician appointments was delayed. The delay in diagnosis could potentially affect outcomes for the patient.

Date of Complication

Date the complication affected treatment

MM/DD/YYYY

Consequence of Complication

Indicates the consequence that resulted from the consequence

R-Refused: a patient declines to receive all or part of recommended treatment plan

D-Delayed: a complication results in delay of planned treatment

S-Stopped: a complication results in a planned treatment being discontinued (cannot be given)

C-Changed: a complication results in a change to the treatment plan

COLLABORATIVE STAGE (CS) CLINICAL-PATHOLOGICAL STAGING SYSTEM

<http://www.cancerstaging.org/cstage/schema/Pages/version0205.aspx>

Years Available for all CS Data Elements:

2005-Breast and Colorectal
2006-Lung
2007-Prostate and Head & Neck
2008-Gyne, Melanoma and Hematopoietic
2009-Urinary and Upper GI
2010-2017 - All Sites

CS Tumor Size

Largest dimension or diameter of the primary tumor, in millimetres

000-No mass/tumor found
001-988-Exact size in millimetres
989-989 millimetres or larger
990-Microscopic focus or foci only and no size of focus is given
991-Described as "less than 1 cm"
992-Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"
993-Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"
994-Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995-Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
996-998-Site-Specific Code where needed
999-Unknown; size not stated not documented in patient record

CS Extension

How far the tumor has directly spread. Identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighbouring organs

000-In situ; non-invasive
###-SITE/HISTOLOGY-SPECIFIC CODES
800-Further contiguous extension
950-No evidence of primary tumor
999-Unknown; extension not stated
Primary tumor cannot be assessed
Not documented in patient record

CS Tumor Size/Ext Eval

Derives the staging basis for the T category in the TNM system. In most circumstances it records how the codes for the two items “CS Tumor Size” and “CS Extension” were determined, based on the diagnostic methods employed.

0-Does not meet criteria for AJCC pathologic staging: No surgical resection done.

Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence.

1-Does not meet criteria for AJCC pathologic staging: No surgical resection done.

Evaluation based on endoscopic examination, diagnostic biopsy, including fine needle aspiration biopsy, or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used. See Notes 1 and 2 below.

2-Meets criteria for AJCC pathologic staging: No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy). See Note 3 below.

3-Either meets criteria for AJCC pathologic staging: Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed AND Evaluation based on evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination of the resected specimen. No surgical resection done. Evaluation based on positive biopsy of highest T classification.

5-Does not meet criteria for AJCC γ -pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy and tumor size/extension based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).

6-Surgical resection performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologic evidence, because pathologic evidence at surgery is more extensive than clinical evidence before treatment.

8-Meets criteria for autopsy (a) staging: Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy)

9-Unknown if surgical resection done, Not assessed; cannot be assessed, Unknown if assessed, Not documented in patient record

CS Lymph Nodes

Identifies the regional lymph nodes involved with cancer at the time of diagnosis

000-None; no regional lymph node involvement

###-SITE/HISTOLOGY-SPECIFIC CODES

999- Unknown; regional lymph nodes not stated, Regional lymph node(s) cannot be assessed, Not documented in patient record

For schemas that do not use the CS Lymph Nodes field

988-Not applicable; Information not collected for this schema

CS Lymph Nodes Evaluation

Used primarily to derive the staging basis for the N category in the TNM system. It records how the code for the item "CS Lymph Nodes" was determined, based on the diagnostic methods employed and their intent.

0-Does not meet criteria for AJCC pathologic staging: No regional lymph nodes removed for examination. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.

1-Does not meet criteria for AJCC pathologic staging based on at least one of the following criteria: No regional lymph nodes removed for examination. Evaluation based on endoscopic examination or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used OR Fine needle aspiration, incisional or core needle biopsy, or excisional biopsy of regional lymph nodes or sentinel nodes as part of the diagnostic workup WITHOUT removal of the primary site adequate for pathologic T classification (treatment).

2-Meets criteria for AJCC pathologic staging: No regional lymph nodes removed for examination, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).

3-Meets criteria for AJCC pathologic staging based on at least one of the following criteria: Any microscopic assessment of regional nodes (including FNA, incisional or core needle biopsy, excisional biopsy, sentinel node biopsy or node resection) WITH removal of the primary site adequate for pathologic T classification (treatment) or biopsy assessment of the highest T category OR Any microscopic assessment of a regional node in the highest N category, regardless of the T category information.

5-Does not meet criteria for AJCC γ -pathologic (γp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy and lymph node evaluation based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant treatment) is more extensive (see code 6)

6-Meets criteria for AJCC γ -pathologic (γp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on pathologic evidence, because the pathologic evidence at surgery is more extensive than clinical evidence before treatment.

8-Meets criteria for AJCC autopsy (a) staging: Evidence from autopsy; tumor was unsuspected or undiagnosed prior to autopsy.

9-Unknown if lymph nodes removed for examination, Not assessed; cannot be assessed, Unknown if assessed, Not documented in patient record. For sites that have no TNM staging: Not applicable; staging basis is displayed as a blank.

Regional Lymph Nodes Positive

Records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases

00-All nodes examined negative

01 – 89-1 to 89 nodes positive (code exact number of nodes positive)

90-90 or more nodes positive

95-Positive aspiration or core biopsy of lymph node(s).

97-Positive nodes - number unspecified.

98-No nodes examined.

99-Unknown whether nodes are positive; not applicable; not documented in patient record.

Regional Lymph Nodes Examined

Records the total number of regional lymph nodes that were removed and examined by the pathologist

00-No nodes examined

01 – 89-1 to 89 nodes examined (code the exact number of regional nodes examined)

90-90 or more nodes examined

95-No regional nodes removed, but aspiration or core biopsy of regional nodes performed

96-Regional lymph node removal documented as a sampling, and the number of nodes unknown/not stated.

97-Regional lymph node removal documented as dissection, and the number of nodes unknown/not stated.

98-Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but the number unknown.

99-Unknown whether nodes were examined; not applicable or negative; not documented in patient record.

CS Metastasis Diagnosis

Identifies the distant site(s) of metastatic involvement at time of diagnosis

00-No distant metastasis

10-Distant lymph node(s)

###-SITE/HISTOLOGY-SPECIFIC CODES WHERE NEEDED

40-Distant metastases except code 10, Carcinomatosis

###-SITE/HISTOLOGY-SPECIFIC CODES WHERE NEEDED

50-40 + 10

60-Distant metastasis, NOS, Stated as M1 with no other information on distant metastasis

99-Unknown; distant metastasis not stated, Distant metastasis cannot be assessed, Not documented in patient record

CS Metastasis Evaluation

Records how the code for the item “CS Mets at DX” was determined based on the diagnostic methods employed

0-Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on physical examination, imaging examination, and/or other non-invasive clinical evidence. No pathologic examination of metastasis performed or pathologic examination was negative.

1-Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on endoscopic examination or other invasive technique, including surgical observation without biopsy. No pathologic examination of metastasis performed or pathologic examination was negative.

2-Meets criteria for AJCC pathologic staging of distant metastasis: No pathologic examination of metastatic specimen done prior to death, but positive metastatic evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).

3-Meets criteria for AJCC pathologic staging of distant metastasis: Specimen from metastatic site microscopically positive WITHOUT pre-surgical systemic treatment or radiation OR specimen from metastatic site microscopically positive, unknown if pre-surgical systemic treatment or radiation performed OR specimen from metastatic site microscopically positive prior to neoadjuvant treatment

5-Does not meet criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on clinical evidence.

6-Meets criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on pathologic evidence.

8-Meets criteria for autopsy (a) staging of distant metastasis: Evidence from autopsy based on examination of positive metastatic tissue AND tumor was unsuspected or undiagnosed prior to autopsy.

9-Not assessed; cannot be assessed, Unknown if assessed, Not documented in patient record. For sites with no TNM staging: Not applicable.

CS Metastasis at Diagnosis – Bone

Identifies whether bone is an involved metastatic site.

0-None; no bone metastases

1-Yes

8-Not applicable

9-Unknown whether bone is involved metastatic site, Not documented in patient record

CS Metastasis at Diagnosis – Brain

Identifies whether brain is an involved metastatic site.

0-None; no brain metastases

1-Yes

8-Not applicable

9-Unknown whether bone is involved metastatic site, Not documented in patient record

CS Metastasis at Diagnosis – Liver

Identifies whether liver is an involved metastatic site.

0-None; no liver metastases

1-Yes

8-Not applicable

9-Unknown whether bone is involved metastatic site, Not documented in patient record

CS Metastasis at Diagnosis – Lung

Identifies whether lung is an involved metastatic site.

0-None; no lung metastases

1-Yes

8-Not applicable

9-Unknown whether bone is involved metastatic site, Not documented in patient record

CS SITE SPECIFIC FACTORS (SSF)

Site-specific factors (SSF's) differ based on primary cancer site. For a list of the SSF's SCA collects refer to page 45 - Collaborative Stage (CS) Site Specific Factors (SSF) SCA Collects.

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival.

SSF's serve a variety of purposes in CS.

Required to support TNM mapping. Some SSFs provide additional information beyond the 9 core CS fields and are necessary for mapping to T, N, M, or stage group. Examples are the number of positive axillary lymph nodes for breast, extracapsular extension for head and neck sites, and the thickness of a malignant melanoma of the skin or mucous membrane.

In general, these will be required by COC facilities and SEER.

Tumor Markers and Lab Values. Some SSFs are tumor markers or lab values of prognostic significance for various sites, such as CA-125 for ovary, CA 19-9 for GI sites, alpha fetoprotein and hCG for testis, KRAS for colon and rectum, and Ki-67 for CNS and various eye sites.

Prognostic/Predictive Items. A number of SSFs are included because of their prognostic or predictive value, such as the Gleason tertiary pattern for prostate, and the various international prognostic indices for lymphoma, such as the IPI for aggressive lymphomas, FLIPI for follicular lymphomas, and the IPS for Hodgkin lymphoma.

Special Interest/Future Research. As part of the effort to be clinically relevant, the seventh edition chapter authors included items of special interest for future research, such as the presence of microsatellite instability for GI cancers and tumor infiltrating lymphocytes (TIL) for Merkel cell carcinoma of the skin.

Other Clinically Significant Information. Some data items pertain to the patient's history of other diseases, such as Sjogren's syndrome for ocular lymphoma, a history of asbestos exposure for pleural mesothelioma, and a particular gene mutation present in many retinoblastoma cases.

For schemas that do not use this site-specific factor:

988-Not applicable for this site

CS – SSF1

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF2

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF3

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF4

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF5

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF6

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF7

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF8

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF9

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF10

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF11

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF12

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF13

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF14

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF15

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF16

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF17

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF18

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF19

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF20

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF21

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF22

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF23

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF24

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival

CS – SSF25

Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival. SSF25 is used as a Schema Discriminator to help determine what schema to use in some sites.

Overall TNM Stage Grp

(UP TO AND INCLUDING 2009 AS AVAILABLE FOR SITES NOT LISTED IN THE ABOVE TABLE, 2010-2017) {AJCC STAGE IS DERIVED FROM CS CODED FIELDS USING THE CS ALGORITHM}

Because each cancer type has its own classification system, letters and numbers do not always mean the same thing for every kind of cancer. Once the T, N, and M are determined, they are combined, and an overall stage of 0, I, II, III, IV is assigned. Sometimes these stages are subdivided as well, using letters such as IIIA and IIIB.

Stage 0-carcinoma in situ.

Stage I-cancers are localized to one part of the body. Stage I cancer can be surgically removed if small enough.

Stage II-cancers are locally advanced. Stage II cancer can be treated by chemo, radiation, or surgery.

Stage III-cancers are also locally advanced. Whether a cancer is designated as Stage II or

Stage III can depend on the specific type of cancer; for example, in Hodgkin's Disease, Stage II indicates affected lymph nodes on only one side of the diaphragm, whereas Stage III indicates affected lymph nodes above and below the diaphragm. The specific criteria for Stages II and III therefore differ according to diagnosis. Stage III can be treated by chemo, radiation, or surgery.

Stage IV-cancers have often metastasized, or spread to other organs or throughout the body. Stage IV cancer can be treated by chemo, radiation, or surgery.

T-Value - TNM Stage

(UP TO AND INCLUDING 2009 AS AVAILABLE FOR SITES NOT LISTED IN THE ABOVE TABLE, 2010-2017)

Extent of the tumor

TX-Primary tumor cannot be evaluated

T0-No evidence of primary tumor

Tis-Carcinoma in situ (early cancer that has not spread to neighbouring tissue)

T1-T4-Size and/or extent of the primary tumor

N-Value – TNM Stage

(UP TO AND INCLUDING 2009 AS AVAILABLE FOR SITES NOT LISTED IN THE ABOVE TABLE, 2010-2017)

Extent of spread to the lymph nodes (N)

NX-Regional lymph nodes cannot be evaluated

N0- No regional lymph node involvement (no cancer found in the lymph nodes)

N1-N3- Involvement of regional lymph nodes (number and/or extent of spread)

M-Value – TNM Stage

(UP TO AND INCLUDING 2009 AS AVAILABLE FOR SITES NOT LISTED IN THE ABOVE TABLE, 2010-2017)

Presence of metastasis

M0- No distant metastasis (cancer has not spread to other parts of the body)

M1- Distant metastasis (cancer has spread to distant parts of the body)

REVIEW INFORMATION/CASE SUMMARY (details occurring after initial diagnosis & treatment)

Source Document Type (2010-Current)

Type of document used to code a review

- 00-No Document Rec'd
- 01-Pathology
- 02-Cytology
- 03-Radiology
- 05-Operative Report
- 06-Internal note
- 07-RT Information
- 10-Pharmacy RX
- 11-External note
- 12-FBM Letter
- 13-Patient Letter
- 14-Autopsy
- 15-Death Certificate
- 16-Other
- 17-Historic
- 18-FD Review
- 20-Hemat Consult
- 21-Vital Statistics – Vital Stat sheet
- 22-Systemic Tx Sheet

Source Document Date

Date of document used to code the review

MM/DD/YYYY

Diagnostic Imaging –2010-Current

Type of radiology report if radiology is chosen, as a source/document type

- 01-Bone Scan
- 02-CT Scan
- 03-Mammogram
- 04-MRI
- 05-Nuclear Medicine Scan
- 06-PET
- 07-Ultrasound
- 08-X-Ray

Disease/Tumor Status

Indicates the patient disease/tumor status at time of review/follow-up

- 1-Free (NED)-No evidence of disease
- 2-Not free this tumor
- 9-Unknown tumor status

Disease/Tumor Status Date

Date of patient's disease/tumor status

MM/DD/YYYY

Recurrence Identified – 2010-Current

Method used to identify the recurrence of cancer. (Multiple Primary & Histology (MP/H) rules direct us if the cancer is a recurrence or a new primary)

- C-Clinical
- P-Pathological
- R-Radiological
- H-Historical

Recurrence Eliminated – 2010-Current

Method used to remove and/or treat the cancer recurrence and there is no more recurrent cancer present

- C-Chemo
- I-Immuno
- M-Multiple
- O-Other
- R-Radiation
- S-Surgery
- T-Transplant
- U-Unknown
- H-Historical

Date of Recurrence

Date recurrence was diagnosed. Date of source document would indicate the date of recurrence.

MM/DD/YYYY

Site of Metastasis

The four-digit alpha-numeric code for the metastatic cancer site in ICD-O (International Classification of Diseases for Oncology)

C000 to C809

Date of Metastasis

Date the metastasis was diagnosed

MM/DD/YYYY

***Metastasis Identified* – 2010-Current**

How the metastasis were diagnosed

- C-Clinical
- P-Pathological
- R-Radiological
- H-Historical

***Metastasis Eliminated* – 2010-Current**

How the metastasis was treated to eliminate the metastasis.

- C-Chemo
- I-Immuno
- M-Multiple
- O-Other
- R-Radiation
- S-Surgery
- T-Transplant
- U-Unknown
- H-Historical data

Biopsy at Review

Chosen if biopsy was performed

Date of Biopsy at Review

Date of biopsy performed

MM/DD/YYYY

Biopsy Code(s) at Review

ICD-9-CM procedure code a biopsy performed. Only one biopsy code is captured

Numerical code

Surgery at Review

Chosen if surgery was performed

Date of Surgery at Review

Date of surgery performed

MM/DD/YYYY

Surgery Code(s) at Review

ICD-9-CM procedure code for the surgery/surgeries performed.

Numerical code

Procedure at Review

Chosen if procedure was performed

Date of Procedure at Review

Date of procedure performed

MM/DD/YYYY

Procedure Code(s) at Review

ICD-9-CM procedure code for the procedures/scopes performed.

Numerical code

Chemo at Review

Selected if Chemo was given

Start Date of Chemo

Start date of chemo

MM/DD/YYYY

End Date of Chemo –2010-Current

End date of chemo

MM/DD/YYYY

Radiation Therapy at Review

Selected if Radiation was given

Start Date of Radiation

Start date of radiation therapy

MM/DD/YYYY

End Date of Radiation –2010-Current

End date of radiation

MM/DD/YYYY

Hormone at Review

Selected if Hormone was given

Start Date of Hormone

Start date of hormone

MM/DD/YYYY

End Date of Hormone -2010-Current

End date of hormone

MM/DD/YYYY

Immuno Therapy at Review

Selected if Immuno was given

Start Date of Immuno Therapy

Start date of immune therapy

MM/DD/YYYY

End Date of Immuno Therapy – 2010-Current

End date of immune therapy

MM/DD/YYYY

Transplant at Review

Selected if a Transplant was performed

Start Date of Transplant

Start date of transplant

MM/DD/YYYY

Other Treatment at Review

Selected if other treatment was given

Start Date of Other Treatment

Start date of other treatment

MM/DD/YYYY

End Date of Other Treatment – 2010-Current

End date of other treatment

MM/DD/YYYY

Complication at Review

Complication is a physical condition/disease affecting the patient's status that delays, alters or prevents the normal course of treatment.

V64.1-Contraindication. Any health condition preventing, stopping or delaying treatment, including disease progression

V64.2-Patient refusal or discontinuation of recommended treatment or intentional non-compliance

V64.3-Other reasons. Any other factors that delay the treatment such as winter storm, family member is sick, planned holidays, seeding and harvesting

995.2-Unusual adverse side effect of drug. Usually results in a change or drug regime

990-Radiation sickness. Adverse effect from Radiation that stops treatment

459.2-Superior Vena Cava Obstruction (SVC)

336.9-Cord Compression (CC)

996.8-Graft vs Host Disease (GVHD)

New for 2020:

U07.1-COVID-19 virus identified. Patients identified with having COVID-19 virus and therefore could not proceed with planned treatment.

U07.2-COVID-19 complication due to pandemic. Patients who do not have the virus but whose treatment was affected as a result of scheduling delays or other issues related to the pandemic. Code is also used for patients whose diagnosis, screening appointments, or initial physician appointments was delayed. The delay in diagnosis could potentially affect outcomes for the patient.

Date of Complication

Date of the complication

MM/DD/YYYY

Consequence of Complication – 2019-Current or Not Applicable

Indicates the consequence that resulted from the consequence

R-Refused: a patient declines to receive all or part of recommended treatment plan

D-Delayed: a complication results in delay of planned treatment

S-Stopped: a complication results in a planned treatment being discontinued (cannot be given)

C-Changed: a complication results in a change to the treatment plan

Date of Last Follow-up

Date of last follow-up

MM/DD/YYYY

DEATH INFORMATION

Date of Death

Date of patient's death. Only month and year will be released. Day will not be released as the day has the potential to identify a patient.

MM/YYYY

Underlying Cause of Death (UCOD) (Primary Cause of Death)

Indicates the underlying cause of death. International Classification of Diseases coding manual is used to collect the alpha numeric UCOD code.

Multiple Cause of Death (Secondary Cause of Death)

Indicates the multiple cause(s) of death after the UCOD has been determined. International Classification of Diseases coding manual is used to collect the alpha numeric multiple cause(s) of death code.

Place of Death

City or town where the patient died

Collaborative Stage (CS) Site Specific Factors (SSF) SCA Collects

Collaborative Stage (CS) Site Specific Factors (SSF) SCA Collects – Dependent on Site –
2007-2017

For additional details: <http://www.cancerstaging.org/cstage/schema/Pages/version0205.aspx>

BONE & SOFT TISSUE:

Bone

(C40.0-C40.3, C40.8-C40.9, C41.0-C41.4, C41.8-C41.9)

SSF 3-Percent Necrosis Post Neoadjuvant Chemotherapy

Gastrointestinal Stromal Tumors (GIST) of Peritoneum and Retroperitoneum

(C48.0-C48.2, C48.8)

SSF 5-Mitotic Count

SSF 6-KIT Gene Immunohistochemistry (IHC)

SSF10-Location of Primary Tumor

Soft Tissue-Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues (C47.0-C47.6, C47.8-C47.9, C49.0-C49.6, C49.8-C49.9)

SSF 1-Grade for Sarcomas

BRAIN & CNS:

Brain-Brain and Cerebral Meninges

(C70.0, C71.0-C71.9)

SSF 1-World Health Organization (WHO) Grade Classification

CNS Other- Other Parts of Central Nervous System

(C70.1, C70.9, C72.0-C72.5, C72.8-C72.9)

SSF 1-World Health Organization (WHO) Grade Classification

Intracranial Gland- Pituitary Gland, Craniopharyngeal Duct, and Pineal Gland

(C75.1, C75.2, C75.3)

SSF 1-World Health Organization (WHO) Grade Classification

BREAST:

Breast

(C50.0-C50.6, C50.8-C50.9)

SSF 1-Estrogen Receptor (ER) Assay

SSF 2-Progesterone Receptor (PR) Assay

SSF 3-Number of Positive Ipsilateral Level I-II Axillary Lymph Nodes
SSF 4-Immunohistochemistry (IHC) of Regional Lymph Nodes
SSF 5-Molecular (MOL) Studies of Regional Lymph Nodes
SSF 6-Size of Tumor-Invasive Component
SSF 7-Nottingham or Bloom-Richardson (BR) Score/Grade
SSF 8-HER2: Immunohistochemistry (IHC) Lab Value
SSF 9-HER2: Immunohistochemistry (IHC) Test Interpretation
SSF 10-HER2: Fluorescence In Situ Hybridization (FISH) Lab Value
SSF 11-HER2: Fluorescence In Situ Hybridization (FISH) Test Interpretation
SSF 12-HER2: Chromogenic In Situ Hybridization (CISH) Lab Value
SSF 13-HER2: Chromogenic In Situ Hybridization (CISH) Test Interpretation
SSF 14-HER2: Result of Other or Unknown Test
SSF 15-HER2: Summary Result of Testing
SSF 16-Combinations of ER, PR, and HER2 Results

ENDOCRINE SYSTEM:

Adrenal Gland

(C74.0-C74.1, C74.9)

No SSF's collected

Endocrine Other

(C37.9, C75.0, C75.4-C75.5, C75.8-C75.9)

No SSF's collected

Thyroid

(C73.9)

SSF 1-Solitary vs Multifocal Tumor

EYE:

Conjunctiva-(excluding Retinoblastoma, Malignant Melanoma, Kaposi Sarcoma, and Lymphoma)

(C69.0)

SSF 1-Tumor Size

Eye Other- Cornea, Retina, Choroid, Ciliary Body, Iris, Overlapping Lesion of Eye, and Other Eye (excluding Melanoma and Retinoblastoma)

(C69.1-C69.4, C69.8-C69.9)

No SSF's collected

Lacrimal Gland-(excluding lymphoma)

(C69.5)

SSF 25-Schema Discriminator: Lacrimal Gland/Lacrimal Sac

Lacrimal Sac-(excluding lymphoma)
(C69.5)

SSF 25-Schema Discriminator: Lacrimal Gland/Lacrimal Sac

Orbit-(excluding lymphoma)
(C69.6)

No SSF's collected

Retinoblastoma
(C69.0-C69.6, C69.8-C69.9)

SSF 1-Extension Evaluated at Enucleation

GYNECOLOGIC:

Adnexa Uterine Other- Broad and Round Ligaments, Parametrium, Uterine Adnexa
(C57.1-C57.4)

No SSF's collected

Cervix-Cervix Uteri
(C53.0-C53.1, C53.8-C53.9)

No SSF's collected

Fallopian Tube
(C57.0)

No SSF's collected

Genital Female Other-Other and Unspecified Female Genital Organs
(C57.7-C57.9)

No SSF's collected

Ovary
(C56.9)

SSF 1-Carbohydrate Antigen 125 (CA-125)

Uterus (Corpus Adenosarcoma)
(C54.0-C54.3, C54.8-C54.9, C55.9)

SSF 2-Peritoneal Cytology

Uterus (Corpus Carcinoma)-Carcinoma and Carcinosarcoma of Corpus Uteri; Uterus, NOS
(excluding Placenta and Adenosarcoma, Leiomyosarcoma, and Endometrial Stromal Sarcoma
(ESS))

(C54.0-C54.3, C54.8-C54.9, C55.9)

SSF 2-Peritoneal Cytology

Uterus (Corpus Sarcoma)-Sarcoma (Leiomyosarcoma and Endometrial Stromal Sarcoma) of the Corpus Uteri; Uterus, NOS (excluding Placenta and Adenosarcoma, Carcinoma, and Carcinosaroma)

(C54.0-C54.3, C54.8-C54.9, C55.9)

SSF 2-Peritoneal Cytology

Peritoneum Female Genital- Peritoneum for Females Only

(C48.1-C48.2, C48.8)

SSF 1-Carbohydrate Antigen 125 (CA-125)

SSF 25-Schema Discriminator: Peritoneum/PeritoneumFemaleGen

Placenta

(C58.9)

SSF 1-Prognostic Scoring Index

Vagina

(C52.9)

No SSF's collected

Vulva-(including Skin of Vulva) (excluding Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas)

(C51.0-C51.2, C51.8-C51.9)

SSF 11-Regional Lymph Node – Laterality

HEAD & NECK:

Buccal Mucosa-Cheek (Buccal) Mucosa, Vestibule (excluding Malignant Melanoma)

(C06.0-C06.1)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Epiglottis Anterior-Anterior Surface of Epiglottis (excluding Malignant Melanoma)

(C10.1)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head

and Neck

SSF 9- Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Floor of Mouth-(excluding Malignant Melanoma)

(C04.0-C04.1, C04.8-C04.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Gum Lower-Gum, Lower and Retromolar Area (excluding Malignant Melanoma)

(C03.1, C06.2)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Gum Other- Gum, NOS (excluding Malignant Melanoma)

(C03.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Gum Upper-(excluding Malignant Melanoma)

(C03.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Hypopharynx-Pyiform Sinus, Hypopharynx, Laryngopharynx (excluding Malignant Melanoma)

(C12.9, C13.0-C13.2, C13.8-C13.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Larynx Glottic- (excluding Malignant Melanoma)

(C32.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Larynx Other-Laryngeal Cartilage, Overlapping Lesion of Larynx, and Larynx, NOS (excluding Malignant Melanoma)

(C32.3, C32.8-C32.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Larynx Subglottic-(excluding Malignant Melanoma)

(C32.2)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Larynx Supraglottic-(excluding Malignant Melanoma)

(C32.1)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Lip Lower-(excluding Malignant Melanoma)
(C00.1, C00.4, C00.6)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Lip Other-(Vermilion or Labial Mucosa) (excluding Malignant Melanoma)
(C00.2, C00.5, C00.8-C00.9)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Lip Upper-(Vermilion or Labial Mucosa) (excluding Malignant Melanoma)
(C00.0, C00.3)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Middle Ear
(C30.1)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Mouth Other-(excluding Malignant Melanoma)

(C05.8-C05.9, C06.8-C06.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Nasal Cavity-(excluding Malignant Melanoma)

(C30.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Nasopharynx-(excluding Malignant Melanoma)

(C11.0-C11.3, C11.8-C11.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

SSF 25-Schema Discriminator: Nasopharynx/Pharyngeal Tonsil

Oropharynx-(excluding Malignant Melanoma)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

SSF 10-Human Papilloma Virus (HPV) Status

Palate Hard-(excluding Malignant Melanoma)
(C05.0)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Palate Soft-(excluding Malignant Melanoma)
(C05.1-C05.2)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck
- SSF 10-Human Papilloma Virus (HPV) Status

Parotid Gland
(C07.9)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Pharyngeal Tonsil-(excluding Malignant Melanoma)
(C11.1)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck
- SSF 10-Human Papilloma Virus (HPV) Status
- SSF 25-Schema Discriminator: Nasopharynx/Pharyngeal Tonsil

Pharynx Other-Pharynx, NOS, and Overlapping Lesion of Lip, Oral Cavity, and Pharynx (excluding Malignant Melanoma)

(C14.0, C14.2, C14.8)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Salivary Gland Other-Other and Unspecified Major Salivary Glands

(C08.1, C08.8-C08.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Sinus Ethmoid-(excluding Malignant Melanoma)

(C31.1)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Sinus Maxillary-(excluding Malignant Melanoma)

(C31.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Sinus Other-Accessory (Paranasal) Sinuses (excluding Malignant Melanoma)
(C31.2-C31.3, C31.8-C31.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Submandibular Gland
(C8.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Thyroid
(C73.9)

SSF 1-Solitary vs Multifocal Tumor

Tongue Anterior-Anterior 2/3 of Tongue, Tip, Border, and Tongue, NOS (excluding Malignant Melanoma)

(C02.0-C02.3, C02.8-C02.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Tongue Base-Base of Tongue and Lingual Tonsil (excluding Malignant Melanoma)
(C01.9, C02.4)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

SSF 10-Human Papilloma Virus (HPV) Status

HEPATOBIILIARY:

Ampulla of Vater-(excluding Neuroendocrine Tumor)

(C24.1)

No SSF's collected

Biliary Other-Other Biliary and Biliary, NOS

(C24.8-C24.9)

No SSF's collected

Bile Ducts Perihilar

(C24.0 Extrahepatic bile duct)

SSF 25- Schema Discriminator: BileDuctsDistal/BileDuctsPerihilar/CysticDuct

Cystic Duct

(C24.0)

SSF 25- Schema Discriminator: BileDuctsDistal/BileDuctsPerihilar/CysticDuct

Distal Bile Duct

(C24.0 Extrahepatic bile duct)

SSF 25-Schema Discriminator: BileDuctsDistal/BileDuctsPerihilar/CysticDuct

Gallbladder

(C23.9)

No SSF's collected

Intrahepatic Bile Duct

(C22.0, C22.1)

SSF 1-Alpha Fetoprotein (AFP) Interpretation

SSF 2-Fibrosis Score

SSF 10-Tumor Growth Pattern

Liver

(C22.0, C22.1)

SSF 1-Alpha Fetoprotein (AFP) Interpretation

SSF 2-Fibrosis Score

Neuroendocrine Tumors (NET) of Ampulla of Vater

(C24.1)

No SSF's collected

Pancreas Body/Tail
(C25.1-C25.2)

No SSF's collected

Pancreas Head
(C25.0)

No SSF's collected

Pancreas Other
(C25.3-C25.4, C25.7-C25.9)

No SSF's collected

ILL-DEFINED SITES, OTHER SITES & UNKNOWN PRIMARY:

Ill Defined Other-Other and Ill-Defined Sites, Unknown Primary Site
(C42.0-C42.4, C76.0-C76.5, C76.7-C76.8, C77.0-C77.5, C77.8-C77.9, C80.9)

No SSF's collected

LOWER GASTROINTESTINAL:

Anus-Anus, Anal Canal, and Other Parts of Rectum
(C21.0-C21.2, C21.8)

No SSF's collected

Appendix-Carcinomas of the Appendix-(excluding Carcinoid Tumor and Neuroendocrine Carcinoma)

(C18.1)

SSF 1-Carcinoembryonic Antigen (CEA)

SSF 2-Clinical Assessment of Regional Lymph Nodes

SSF 11-Histopathologic Grading

Carcinoid Appendix-Carcinoid Tumor and Neuroendocrine Carcinoma of Appendix
(C18.1)

SSF 2-Clinical Assessment of Regional Lymph Nodes

Colon-(excluding Appendix, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor)

(C18.0, C18.2-C18.9)

SSF 1-Carcinoembryonic Antigen (CEA)

SSF 2-Clinical Assessment of Regional Lymph Nodes

SSF 4-Tumor Deposits

SSF 7-Microsatellite Instability (MSI)

Digestive Other-Other and Ill-Defined Digestive Organs
(C26.0, C26.8-C26.9)
No SSF's collected

Gastrointestinal Stromal Tumor (GIST) of Appendix
(C18.1)
SSF 11-Mitotic Count
SSF 12-KIT Gene Immunohistochemistry (IHC)

Gastrointestinal Stromal Tumor (GIST) of Colon
(C18.0, C18.2-C18.9)
SSF 11-Mitotic Count
SSF 12-KIT Gene Immunohistochemistry (IHC)

Gastrointestinal Stromal Tumor (GIST) of Peritoneum-GIST of Peritoneum and Retroperitoneum
(C48.0-C48.2, C48.8)
SSF 5-Mitotic Count
SSF 6-KIT Gene Immunohistochemistry (IHC)
SSF 10-Location of Primary Tumor

Gastrointestinal Stromal Tumor (GIST) of Rectum & Rectosigmoid
(C19.9, C20.9)
SSF 11-Mitotic Count
SSF 12-KIT Gene Immunohistochemistry (IHC)

Neuroendocrine Tumors (NET) of Colon-(excluding Appendix)
(C18.0, C18.2-C18.9)
SSF 2-Clinical Assessment of Regional Lymph Nodes

Neuroendocrine Tumors (NET) of Rectum and Rectosigmoid
(C19.9, C20.9)
SSF 2-Clinical Assessment of Regional Lymph Nodes

Neuroendocrine Tumors (NET) of Small Intestine
(C17.0-C17.3, C17.8-C17.9)
No SSF's collected

Rectum, Rectosigmoid
(C19.9, C20.9)
SSF 1-Carcinoembryonic Antigen (CEA)
SSF 2-Clinical Assessment of Regional Lymph Nodes
SSF 4-Tumor Deposits
SSF 6-Circumferential Resection Margin (CRM)
SSF 7-Microsatellite Instability (MSI)

LUNG:

Lung

(C34.0-C34.3, C34.8-C34.9)

SSF 1-Separate Tumor Nodules - Ipsilateral Lung

LYMPHOMA & HEMATOPOIETIC:

Kaposi Sarcoma-Kaposi Sarcoma of All Sites

No SSF's collected

Lymphoma-Hodgkin and Non-Hodgkin Lymphomas of All Sites (excluding Mycosis Fungoides and Sezary Disease)

(M-9590-9699, 9702-9729, 9735, 9737, 9738 (EXCEPT C44.1, C69.0, C69.5-C69.6)

(M-9811-9818, 9823, 9827, 9837 (EXCEPT C42.0, C42.1, C42.4, C44.1, C69.0, C69.5-C69.6)

SSF 1-Associated with HIV/AIDS

SSF 2-Systemic Symptoms at Diagnosis

SSF 3-International Prognostic Index (IPI)

Lymphoma Ocular Adnexa-Lymphoma of the Ocular Adnexa and Skin of Eyelid

(C44.1, C69.0, C69.5-C69.6)

(M-9590-9699, 9702-9738, 9811-9818, 9820-9837)

SSF 1-Associated with HIV/AIDS

SSF 2-Systemic Symptoms at Diagnosis

SSF 3-International Prognostic Index (IPI)

Mycosis Fungoides and Sezary Disease-Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum

(C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2)

SSF 1- Peripheral Blood Involvement

Myeloma Plasma Cell Disorders-Plasma Cell Disorders including Myeloma

(9731 Plasmacytoma, NOS (except C441, C690, C695-C696)

(9732 Multiple myeloma (except C441, C690, C695-C696)

(9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696)

No SSF's collected

HemeRetic-Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

(Morphology-See list of specific histologies online. All primary sites (C00.0-C80.9) are included unless otherwise specified. Schema includes only preferred terms from ICD-O-3.

No SSF's collected

MALE GENITALIA:

Genital Male Other- Other and Unspecified Male Genital Organs (excluding Scrotum, Kaposi Sarcoma and Lymphoma)
(C63.0-C63.1, C63.7-C63.9)

No SSF's collected

Penis-(excludes Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease and Other Lymphomas)
(C60.0-C60.2, C60.8-C60.9)

SSF 17-Extranodal Extension of Regional Lymph Nodes

Scrotum-(excluding Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas)
(C63.2)

SSF 12-High Risk Features

SSF 16-Size of Lymph Nodes

Testis

(C62.0-C62.1, C62.9)

SSF 4-Radical Orchiectomy Performed

SSF 5-Size of Metastasis in Lymph Nodes

SSF 13-Post-Orchiectomy Alpha Fetoprotein (AFP) Range

SSF 15-Post-Orchiectomy Human Chorionic Gonadotropin (hCG) Range

SSF 16-Post-Orchiectomy Lactate Dehydrogenase (LDH) Range

MELANOMA (Eye, Head & Neck & Skin):

EYE MELANOMA

Choroid Melanoma

(C69.3)

SSF 2-Measured Basal Diameter

SSF 3-Measured Thickness (Depth)

SSF 4-Size of Largest Metastasis

Ciliary Body Melanoma-(excluding Iris)

(C69.4)

SSF 2-Measured Basal Diameter

SSF 3-Measured Thickness (Depth)

SSF 4-Size of Largest Metastasis

SSF 25-Schema Discriminator: Melanoma Ciliary Body/Melanoma Iris

Conjunctive Melanoma
(C69.0)

SSF 1-Measured Thickness (Depth)
SSF 2-Quadrants

Eye Other Melanoma-(excluding Conjunctiva, Choroid, Ciliary Body, and Iris)
(C69.1, C69.2, C69.5, C69.8-C69.9)
No SSF's collected

Iris Melanoma
(C69.4)

SSF 4-Size of Largest Metastasis
SSF 25-Schema Discriminator: Melanoma Ciliary Body/Melanoma Iris

MELANOMA HEAD & NECK

Melanoma Buccal Mucosa- Malignant Melanoma of Buccal Mucosa
(C06.0-C06.1)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Epiglottis Anterior- Malignant Melanoma of Anterior Surface of Epiglottis
(C10.1)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Floor Mouth- Malignant Melanoma of Floor of Mouth
(C04.0-C04.1, C04.8-C04.9)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Gum Lower- Malignant Melanoma of Lower Gum and Retromolar Area
(C03.1, C06.2)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Gum Other- Malignant Melanoma of Gum, NOS
(C03.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Gum Upper- Malignant Melanoma of Upper Gum
(C03.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Hypopharynx- Malignant Melanoma of Pyriform Sinus, Hypopharynx, and Laryngopharynx
(C12.9, C13.0-C13.2, C13.8-C13.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Larynx Glottic- Malignant Melanoma of Glottic Larynx
(C32.0)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Larynx Other- Malignant Melanoma of Other Larynx
(C32.3, C32.8-C32.9)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Larynx Subglottic- Malignant Melanoma of Subglottic Larynx
(C32.2)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Larynx Supraglottic- Malignant Melanoma of Subglottic Larynx
(C32.2)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck
- SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
- SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
- SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
- SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Lip Lower- Malignant Melanoma of Lower Lip, Lip (Vermilion or Labial Mucosa)
(C00.1, C00.4, C00.6)

- SSF 1-Size of Lymph Nodes
- SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Lip Other- Malignant Melanoma of Other Lip, Lip (Vermilion or Labial Mucosa)
(C00.2, C00.5, C00.8-C00.9)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Lip Upper- Malignant Melanoma of Upper Lip, Lip (Vermilion or Labial Mucosa)
(C00.0, C00.3)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Mouth Other- Malignant Melanoma of Other Mouth
(C05.8-C05.9, C06.8-C06.9)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck
SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Nasal Cavity- Malignant Melanoma of Nasal Cavity
(C30.0)

SSF 1-Size of Lymph Nodes
SSF 3-Levels I-III, Lymph Nodes for Head and Neck
SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck
SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck
SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Nasopharynx- Malignant Melanoma of Nasopharynx (including Pharyngeal Tonsil)
(C11.0-C11.3, C11.8-C11.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Oropharynx- Malignant Melanoma of Tonsil and Oropharynx
(C09.0-C09.1, C09.8-C09.9, C10.0, C10.2-C10.4, C10.8-C10.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Palate Hard- Malignant Melanoma of Hard Palate
(C05.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Palate Soft- Malignant Melanoma of Soft Palate and Uvula
(C05.1-C05.2)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Pharynx NOS and Overlapping Lesions on Lip Oral- Malignant Melanoma of Pharynx, NOS and Overlapping Lesions of Lip, Oral Cavity, and Pharynx
(C14.0, C14.2, C14.8)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Sinus Ethmoid- Malignant Melanoma of Ethmoid Sinus
(C31.1)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Sinus Maxillary- Malignant Melanoma of Maxillary Sinus
(C31.0)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Sinus Other- Malignant Melanoma of Accessory (Paranasal) Sinuses
(C31.2-C31.3, C31.8-C31.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Tongue Anterior- Malignant Melanoma of Anterior Tongue
(C02.0-C02.3, C02.8-C02.9)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

Melanoma Tongue Base- Malignant Melanoma of Base of Tongue and Lingual Tonsil
(C01.9, C02.4)

SSF 1-Size of Lymph Nodes

SSF 3-Levels I-III, Lymph Nodes for Head and Neck

SSF 4-Levels IV-V and Retropharyngeal Lymph Nodes for Head and Neck

SSF 5-Levels VI-VII and Facial Lymph Nodes for Head and Neck

SSF 6-Parapharyngeal, Parotid, and Suboccipital/Retroauricular Lymph Nodes for Head and Neck

SSF 9-Extracapsular Extension Pathologically, Lymph Nodes for Head and Neck

MELANOMA SKIN

Melanoma Skin- Malignant Melanoma of Skin, Vulva, Penis, Scrotum
(C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2)

SSF 1-Measured Thickness (Depth), Breslow Measurement

SSF 2-Ulceration

SSF 3-Clinical Status of Lymph Node Mets

SSF 4-Serum Lactate Dehydrogenase (LDH)

SSF 7-Primary Tumor Mitotic Count/Rate

MERKEL CELL:

Merkel Cell Penis
(C60.0-C60.2, C60.8-C60.9)

SSF 3-Clinical Status of Lymph Node Mets

Merkel Cell Scrotum
(C63.2)

SSF 3-Clinical Status of Lymph Node Mets

Merkel Cell Skin- Merkel Cell Carcinoma of the Skin (excluding Merkel Cell Carcinoma of Penis, Scrotum, and Vulva)
(C44.0, C44.2-C44.9)

SSF 3-Clinical Status of Lymph Node Mets

Merkel Cell Vulva

(C51.0-C51.2, C51.8-C51.9)

SSF 3-Clinical Status of Lymph Node Mets

SSF 11-Regional Lymph Node – Laterality

PERITONEUM & RETROPERITONEUM:

Gastrointestinal Stromal Tumor (GIST) of Peritoneum and Retroperitoneum

(C48.0-C48.2, C48.8)

SSF 5-Mitotic Count

SSF 6-KIT Gene Immunohistochemistry (IHC)

SSF 10- Location of Primary Tumor

Peritoneum-(excluding Gastrointestinal Stromal Tumors and Peritoneum Female Genital M-
8000-8576, 8590-8671, 8930-8934, 8940-9110 for females)

(C48.1-C48.2, C48.8)

SSF 1-Grade for Sarcomas

SSF 25- Schema Discriminator: Peritoneum/PeritoneumFemaleGen

Retroperitoneum

(C48.0)

SSF 1-Grade for Sarcomas

PROSTATE:

Prostate

(C61.9)

SSF 1-Prostatic Specific Antigen (PSA) Lab Value

SSF 2-Prostatic Specific Antigen (PSA) Interpretation

SSF 3-CS Extension - Pathologic Extension

SSF 7-Gleason's Primary Pattern and Secondary Pattern Values on Needle Core

Biopsy/Transurethral Resection of Prostate (TURP)

SSF 8-Gleason's Score on Needle Core Biopsy/Transurethral Resection of Prostate
(TURP)

SSF 9-Gleason's Primary Pattern and Secondary Pattern Values on
Prostatectomy/Autopsy

SSF 10-Gleason's Score on Prostatectomy/Autopsy

SSF 11-Gleason's Tertiary Pattern Value on Prostatectomy/Autopsy

SSF 12-Number of Cores Positive

SSF 13-Number of Cores Examined

SKIN:

Skin-(excluding Skin of Eyelid and Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas)
(C44.0, C44.2-C44.9)

SSF 12-High Risk Features
SSF 16-Size of Lymph Nodes

Skin Eyelid
(C44.1)

SSF 1-Measured Thickness (Depth) for Squamous Cell Carcinoma
SSF 6-Perineural Invasion

TRACHEA, PLEURA, HEART & MEDIASTINUM:

Heart and Mediastinum
(C38.0-C38.3, C38.8)

SSF 1-Grade for Sarcomas

Pleura
(C38.4)

SSF 1-Pleural Effusion

Respiratory Other- Other and Ill-Defined Respiratory Sites and Intrathoracic Organs
(C39.0, C39.8-C39.9)

No SSF's collected

Trachea
(C33.9)

No SSF's collected

UPPER GASTROINTESTINAL:

Esophagus
(C15.0-C15.5, C15.8-C15.9)

SSF 1- Clinical Assessment of Regional Lymph Nodes

EsophagusGEJunction
(C16.0, C16.1, C16.2)

SSF 1-Clinical Assessment of Regional Lymph Nodes
SSF 25-Schema Discriminator: EsophagusGEJunction (EGJ)/Stomach

Gastrointestinal Stromal Tumor (GIST) of Esophagus
(C15.0-C15.5, C15.8-C15.9)
SSF 6-Mitotic Count
SSF 7-KIT Gene Immunohistochemistry (IHC)

Gastrointestinal Stromal Tumor (GIST) of Small Intestine
(C17.0-C17.3, C17.8-C17.9)
SSF 6-Mitotic Count
SSF 7-KIT Gene Immunohistochemistry (IHC)

Gastrointestinal Stromal Tumor (GIST) of Stomach
(C16.0-C16.6, C16.8-C16.9)
SSF 6-Mitotic Count
SSF 7-KIT Gene Immunohistochemistry (IHC)

Neuroendocrine Tumors (NET) of Small Intestine
(C17.0-C17.3, C17.8-C17.9)
No SSF's collected

Neuroendocrine Tumors (NET) of Stomach
(C16.0-C16.6, C16.8-C16.9)
SSF 1-Clinical Assessment of Regional Lymph Nodes

Small Intestine-(excluding Gastrointestinal Stromal Tumor and Neuroendocrine Tumor)
(C17.0-C17.3, C17.8-C17.9)
SSF 2-Clinical Assessment of Regional Lymph Nodes

Stomach-(excluding Gastrointestinal Stromal Tumor and Neuroendocrine Tumor)
(C16.1-C16.6, C16.8-C16.9)
SSF 1-Clinical Assessment of Regional Lymph Nodes
SSF 25-Schema Discriminator: EsophagusGEJunction (EGJ)/Stomach

URINARY:

Bladder
(C67.0-C67.9)
SSF 1-WHO/ISUP Grade
SSF 2-Size of Metastasis in Lymph Nodes

Kidney Parenchyma
(C64.9)
No SSF's collected

Kidney Renal Pelvis
(C65.9, C66.9)
SSF 1-WHO/ISUP Grade

Urethra
(C68.0)
SSF 1-WHO/ISUP Grade

Urinary Other
(C68.1, C68.8-C68.9)
No SSF's collected

Site Specific Data Items (SSDI's) SCA Collects

Site Specific Data Items (SSDI) SCA Collects -2018-Current

For additional details: <https://apps.naaccr.org/ssdi/list/>

Notes:

- Grade Clinical, Grade Pathological and Grade Post Therapy are included in **all** SSDI's for all sites when applicable, therefore, each one will not be listed under each primary site.
- If there isn't a SSDI listed below the site then we don't collect SSDI's for that primary site.
- Schema Discriminator - Identifies additional information needed to generate stage or prognostic/predictive factors that have an effect on stage or survival. Dependent on Cancer Site and Diagnosis Year.
- Dependent on Cancer Site and Diagnosis Year
- Malignant Colon & Rectum cases have actual values for 2018 cases.
- Default/Unknown values are entered for all other sites in 2018.

List is in alphabetically order by primary site.

Adnexa Uterine Other

Primary Site: C571-C574

Histology: 8000-8700, 8720-8790, 9700-9701

Adrenal Gland

Primary Site: C740-C741, C749

Histology: 8000-8671, 8681-8683, 8691, 8720-8790, 9700-9701

Ampulla of Vater

Primary Site: C241

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 9700-9701

Anus

Primary Site: C210-C212, C218

Histology: 8000-8700, 8720-8790, 9700-9701

Appendix

Primary Site: C181

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 9700-9701

CEA (Carcinoembryonic Antigen) Pretreatment Interpretation

0-CEA negative/normal; within normal limits

1-CEA positive/elevated

2-Borderline

3-Undetermined if positive or negative (normal values not available) AND no MD interpretation

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case (If this data item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, CEA (Carcinoembryonic Antigen)

Pretreatment Interpretation not assessed or unknown if assessed

Bile Duct Distal

Primary Site: C240

Histology: 8000-8700, 8720-8790, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate for primary site C240 (extrahepatic bile ducts) for the subsite in which the tumor arose.

1-Perihilar bile duct(s), Proximal extrahepatic bile duct(s), Hepatic duct(s)

Disease=25: Perihilar Bile Ducts

3-Cystic bile duct; cystic duct

Disease=24: Cystic Duct

4-Distal bile duct, Common bile duct, Common duct, NOS

Disease=26: Distal Bile Ducts

5-Diffuse involvement, More than one subsite involved, subsite of origin not stated

Disease=25: Perihilar Bile Ducts

6- Stated as middle extrahepatic bile duct AND treated with combined hepatic and hilar resection

Disease=25: Perihilar Bile Ducts

7- Stated as middle extrahepatic bile duct AND treated with pancreaticoduodenectomy

Disease=26: Distal Bile Ducts

9- Extrahepatic bile ducts, NOS

Disease=25: Perihilar Bile Ducts

Bile Ducts Intrahepatic

Primary Site: C221

Histology: 8000-8700, 8720-8790, 8980, 9700-9701

Bile Ducts Perihilar

Primary Site: C240

Histology: 8000-8700, 8720-8790, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate for primary site C240 (extrahepatic bile ducts) for the subsite in which the tumor arose.

1- Perihilar bile duct(s), Proximal extrahepatic bile duct(s), Hepatic duct(s)

Disease=25: Perihilar Bile Ducts

3- Cystic bile duct; cystic duct

Disease=24: Cystic Duct

4- Distal bile duct, Common bile duct, Common duct, NOS

Disease=26: Distal Bile Ducts

5- Diffuse involvement, More than one subsite involved, subsite of origin not stated

Disease=25: Perihilar Bile Ducts

6- Stated as middle extrahepatic bile duct AND treated with combined hepatic and hilar resection

Disease=25: Perihilar Bile Ducts

7- Stated as middle extrahepatic bile duct AND treated with pancreaticoduodenectomy

Disease=26: Distal Bile Ducts

9- Extrahepatic bile ducts, NOS

Disease=25: Perihilar Bile Ducts

Biliary Other

Primary Site: C248-C249

Histology: 8000-8700, 8720-8790, 9700-9701

Bladder

Primary Site: C670-C679

Histology: 8000-8700, 8720-8790, 9700-9701

Bone Appendicular Skeleton, Trunk, Skull, and Facial Bones

Primary Site: C400-C403, C408-C411, C413, C418-C419

Histology: 8000-8934, 8940-9137, 9141-9582, 9700-9701

Percent Necrosis Post Neoadjuvant

0.0-Tumor necrosis not identified/not present

0.1-100.0-0.1 - 100.0 percent tumor necrosis (Percentage of tumor necrosis to nearest tenth of a percent)

XXX.2-Tumor necrosis present, percent not stated

XXX.8-Not applicable: Information not collected for this case. If this item is required by your standard setter, use of code XXX.8 will result in an edit error.

XXX.9-Not documented in medical record, No histologic examined of primary site, No neoadjuvant therapy, No surgical resection of primary site is performed

Bone Pelvis

Primary Site: C414

Histology: 8000-8934, 8940-9137, 9141-9582, 9700-9701

Percent Necrosis Post Neoadjuvant

0.0-Tumor necrosis not identified/not present

0.1-100.0-0.1 - 100.0 percent tumor necrosis (Percentage of tumor necrosis to nearest tenth of a percent)

XXX.2-Tumor necrosis present, percent not stated

XXX.8-Not applicable: Information not collected for this case. If this item is required by your standard setter, use of code XXX.8 will result in an edit error.

XXX.9-Not documented in medical record, No histologic examined of primary site, No neoadjuvant therapy, No surgical resection of primary site is performed

Bone Spine

Primary Site: C412

Histology: 8000-8934, 8940-9137, 9141-9582, 9700-9701

Percent Necrosis Post Neoadjuvant

0.0-Tumor necrosis not identified/not present

0.1-100.0-0.1 - 100.0 percent tumor necrosis (Percentage of tumor necrosis to nearest tenth of a percent)

XXX.2-Tumor necrosis present, percent not stated

XXX.8-Not applicable: Information not collected for this case. If this item is required by your standard setter, use of code XXX.8 will result in an edit error.

XXX.9-Not documented in medical record, No histologic examined of primary site, No neoadjuvant therapy, No surgical resection of primary site is performed

Brain

Primary Site: C700, C710-C719

Histology: (any behavior) 8000-8700, 8720-8790, 8802, 8810, 8815, 8850, 8890, 8900, 9064, 9070-9071, 9080, 9084-9085, 9100-9105, 9120, 9133, 9140, 9180, 9220, 9362, 9364, 9380-9540, 9680, 9699, 9700-9714, 9751-9759

Primary Site: C700, C710-C719

Histology: (Behavior 0{Benign} or 1{Uncertain}) 8710-8714, 8800-8801, 8803-8806, 8811-8814, 8820-8842, 8851-8881, 8891-8898, 8901-9063, 9065, 9072-9073, 9081-9083, 9086-9091, 9110, 9121-9132, 9135-9137, 9141-9175, 9181-9210, 9221-9361, 9363, 9365-9373, 9541-9582

Primary Site: C700, C710-C719

Histology: (Behavior 0{Benign} or 1{Uncertain}) 9590-9679, 9687-9698, 9716-9742, 9761-9992

Breast

Primary Site: C500-C506, C508-C509

Histology: 8000-8700, 8982-8983, 9700-9701

Primary Site: C501-C506, C508-C509

Histology: 8720-8790

ER (Estrogen Receptor) Summary

0-ER negative

1-ER positive

7-Test ordered, results not in chart

9-Not documented in medical record, Cannot be determined (indeterminate), ER (Estrogen Receptor) Summary status not assessed or unknown if assessed

PR (Progesterone Receptor) Summary

0-PR negative

1-PR positive

7-Test ordered, results not in chart

9-Not documented in medical record, PR (Progesterone Receptor) Summary status not assessed or unknown if assessed

HER2 Overall Summary

0-HER2 negative; equivocal

1-HER2 positive

7-Test ordered, results not in chart

9-Not documented in medical record, Cannot be determined (indeterminate),

HER2 Overall Summary status not assessed or unknown if assessed

HER2 IHC Summary

0-Negative (Score 0)

1-Negative (Score 1+)

2-Equivocal (Score 2+), Stated as equivocal

3-Positive (Score 3+), Stated as positive

4-Stated as negative, but score not stated

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, Cannot be determined (indeterminate),

HER2 IHC Summary not assessed or unknown if assessed

HER2 ISH Summary

0-Negative [not amplified]

2-Equivocal

3-Positive [amplified]

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, Results cannot be determined (indeterminate), HER2 ISH Summary not assessed or unknown if assessed

Oncotype Dx Recurrence Score – Invasive

000-100-Enter actual recurrence score between 0 and 100

XX4-Stated as less than 11

XX5-Stated as equal to or greater than 11

XX6-Not applicable, in situ case

XX7-Test ordered, results not in chart

XX9-Not documented in medical record, Oncotype Dx Recurrence Score -Invasive not assessed or unknown if assessed

Buccal Mucosa

Primary Site: C060-C061

Histology: 8000-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

- 0.0-Lymph nodes positive for cancer but ENE not identified or negative
- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck

Primary Site: C760

Histology: 8000-8700, 8720-8790, 8941, 9700-9701

Schema Discriminator 1: This schema discriminator is used to discriminate between head and neck tumors with unknown primary site coded as C760. Some situations require that a more specific primary site be assigned.

0-Not Occult

Disease: EOD/SS schema (Ill-Defined, Other; Soft Tissue Other for 8941)

- 1-Occult, Negative cervical nodes (regional head and neck nodes)
Disease: EOD/SS schema (III-Defined, Other; Soft Tissue Other for 8941)
- 2-Not tested for EBV or p16 in head and neck regional nodes (EBV and p16 both unknown)
Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
- 3-Unknown EBV, p16 negative in head and neck regional nodes
Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
- 4-Unknown p16, EBV negative in head and neck regional nodes
Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
- 5-Negative for both EBV and p16 in head and neck regional nodes
Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
- BLANK-Not C760, discriminator does not apply, Positive p16 in head and neck regional nodes, EBV unknown or negative, Assign primary site C109, Positive EBV in head and neck regional nodes, p16 positive, negative, or unknown, Assign primary site C119
Disease: Various, 10: HPV-Mediated (p16+) Oropharyngeal Cancer (C109), (Schema ID 00100: Oropharynx HPV-Mediated (p16+)), 9: Nasopharynx (C119) (Schema ID 00090: Nasopharynx)

Extranodal Extension Head and Neck Pathological

- 0.0-Lymph nodes positive for cancer but ENE not identified or negative
- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Cervix

Primary Site: C530-C531, C538-C539

Histology: 8000-8700, 8720-8790, 8805, 8933, 8980, 9110, 9581, 9700-9701

CNS Other

Primary Site: C701, C709, C720-C721, C728-C729

Histology: (any behavior) 8000-8700, 8720-8790, 8802, 8810, 8815, 8850, 8890, 8900, 9064, 9070-9071, 9080, 9084-9085, 9100-9105, 9120, 9133, 9140, 9180, 9220, 9362, 9364, 9380-9540, 9680, 9699, 9700-9714, 9751-9759

Primary Site: C701, C709, C720-C721, C728-C729

Histology: (Behavior 0{Benign} or 1{Uncertain}) 8710-8714, 8800-8801, 8803-8806, 8811-8814, 8820-8842, 8851-8881, 8891-8898, 8901-9063, 9065, 9072-9073, 9081-9083, 9086-9091, 9110, 9121-9132, 9135-9137, 9141-9175, 9181-9210, 9221-9361, 9363, 9365-9373, 9541-9582

Primary Site: C722, C724-C725

Histology: (any behavior) 9539, 9680, 9699, 9700-9714, 9751-9759

Primary Site: C722, C724-C725

Histology: (Behavior 0{Benign} or 1{Uncertain}) 8710-8714, 8800-8898, 8901-9063, 9065, 9072-9073, 9081-9083, 9086-9091, 9101-9110, 9121-9137, 9141-9210, 9221-9361, 9363-9373, 9540-9582

Primary Site: C723

Histology: (any behavior) 8000-8700, 8720-8790, 9064, 9070, 9080, 9084-9085, 9100, 9140, 9180, 9362, 9380-9420, 9423-9472, 9474-9493, 9501-9521, 9523, 9531-9539, 9680, 9699, 9700-9714, 9751-9759

Primary Site: C723

Histology: (Behavior 0{Benign} or 1{Uncertain}) 8710-8714, 8800-9063, 9065, 9071-9073, 9081-9083, 9086-9091, 9101-9137, 9141-9175, 9181-9361, 9363-9373, 9421, 9473, 9500, 9522, 9530, 9540-9582

Primary Site: C701, C709, C720-C729

Histology: (Behavior 0{Benign} or 1{Uncertain}) 9590-9679, 9687-9698, 9716-9742, 9761-9992

Colon and Rectum

Primary Site: C180, C182-C189, C199, C209

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 9700-9701

CEA (Carcinoembryonic Antigen) Pretreatment Interpretation

0-CEA negative/normal; within normal limits

1-CEA positive/elevated

2-Borderline

3-Undetermined if positive or negative (normal values not available), AND no MD interpretation

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case (If this data item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, CEA (Carcinoembryonic Antigen), Pretreatment Interpretation not assessed or unknown if assessed

Circumferential Resection Margin (CRM)

0.0-Circumferential resection margin (CRM) positive, Margin IS involved with tumor, Described as "less than 0.1 millimeter (mm)"

0.1-99.9-Distance of tumor from margin: 0.1- 99.9 millimeters (mm), (Exact size to nearest tenth of millimeter)

XX.0-100 mm or greater

XX.1-Margins clear, distance from tumor not stated, Circumferential or radial resection margin negative, NOS, No residual tumor identified on specimen

XX.2-Margins cannot be assessed

XX.3-Described as "at least" 1 mm

XX.4-Described as "at least" 2 mm

XX.5-Described as "at least" 3 mm

XX.6-Described as "greater than" 3 mm

XX.7-No resection of primary site, Surgical procedure did not remove enough tissue to measure the circumferential or radial resection margin (Examples include: polypectomy only, endoscopic mucosal resection (EMR), excisional biopsy only, transanal disk excision)

XX.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code XX.8 may result in an edit error.)

XX.9-Not documented in medical record, Circumferential or radial resection margin not assessed or unknown if assessed

Microsatellite Instability (MSI)

0-Microsatellite instability (MSI) stable; microsatellite stable (MSS); negative, NOS AND/OR Mismatch repair (MMR) intact, no loss of nuclear expression of MMR proteins

1-MSI unstable low (MSI-L)

2-MSI unstable high (MSI-H) AND/OR MMR-D (loss of nuclear expression of one or more MMR proteins, MMR protein deficient)

8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 8 may result in an edit error.)

9-Not documented in medical record, MSI-indeterminate, Microsatellite instability not assessed or unknown if assessed

Conjunctiva

Primary Site: C690

Histology: 8000-8700, 9700-9701

Corpus Adenosarcoma

Primary Site: C540-C543, C548-C549, C559

Histology: 8933

Corpus Carcinoma and Carcinosarcoma

Primary Site: C540-C543, C548-C549, C559

Histology: 8000-8700, 8720-8790, 8950, 8980, 9700-9701

Corpus Sarcoma

Primary Site: C540-C543, C548-C549, C559

Histology: 8710-8714, 8800-8932, 8934-8941, 8951-8975, 8981-9137, 9141-9582

Cutaneous Carcinoma of Head and Neck

Primary Site: C000-C002, C006, C440, C442-C444

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700, 8940, 8982

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Cystic Duct

Primary Site: C240

Histology: 8000-8700, 8720-8790, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate for primary site C240 (extrahepatic bile ducts) for the subsite in which the tumor arose.

1-Perihilar bile duct(s), Proximal extrahepatic bile duct(s), Hepatic duct(s)

Disease=25: Perihilar Bile Ducts

3-Cystic bile duct; cystic duct

Disease=24: Cystic Duct

4-Distal bile duct, Common bile duct, Common duct, NOS

Disease=26: Distal Bile Ducts

5-Diffuse involvement, More than one subsite involved, subsite of origin not stated

Disease=25: Perihilar Bile Ducts

6-Stated as middle extrahepatic bile duct AND treated with combined hepatic and hilar resection

Disease=25: Perihilar Bile Ducts

7- Stated as middle extrahepatic bile duct AND treated with pancreaticoduodenectomy
Disease=26: Distal Bile Ducts
9-Extrahepatic bile ducts, NOS
Disease=25: Perihilar Bile Ducts

Digestive Other

Primary Site: C260, C268-C269
Histology: 8000-8700, 8720-8790, 9700-9701

Endocrine Other

Primary Site: C754, C758-C759
Histology: 8000-8700, 8720-8790, 9700-9701

Primary Site: C755
Histology: 8000-8671, 8681-8683, 8691, 8720-8790, 9700-9701

Esophagus (including GE junction) (excluding Squamous)

Primary Site: C150-C155, C158-C159
Histology: 8000-8015, 8021-8046, 8060, 8071-8073, 8075-8076, 8078-8082, 8084-8552, 8561-8700, 8720-8790, 9700-9701

Primary Site: C160
Histology: 8000-8015, 8021-8046, 8060, 8071-8073, 8075-8076, 8078-8082, 8084-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8552, 8561-8682, 8690-8700, 8720-8790, 9700-9701

Primary Site: C150-C155, C158-C159
Histology: 8020

Primary Site: C160
Histology: 8020

Schema Discriminator 1: When primary site code is C160, the cancer will be staged using either the stomach cancer schema or the esophagus schema depending on the distance of the tumor's epicenter into the proximal stomach and whether or not the esophagogastric junction is involved.
Assign the code that best reflects EGJ involvement and the distance of the tumor's epicenter into the proximal stomach.

0-No involvement of esophagus or gastroesophageal junction AND epicenter at any distance into the proximal stomach (including distance unknown)

Disease: 17: Stomach

2-Involvement of esophagus or esophagogastric junction (EGJ) AND epicenter less than or equal to 2 cm into the proximal stomach

Disease: 16 Esophagus AND go to Schema Discriminator 2: Histology
Discriminator for 8020/3

3- Involvement of esophagus or esophagogastric junction (EGJ) AND epicenter greater than 2 cm into the proximal stomach

Disease: 17: Stomach

9-Unknown involvement of esophagus or gastroesophageal junction AND epicenter at any distance into the proximal stomach (including distance unknown)

Disease: 17: Stomach

BLANK-Primary Site is NOT C160, Discriminator is not necessary

Schema Discriminator 2: A schema discriminator is used to discriminate for histology

8020/3: Undifferentiated carcinoma to determine which Stage Group table to use.

1-Undifferentiated carcinoma with squamous component

Disease: 16.1: Esophagus and Esophagogastric Junction: Squamous Cell
Carcinoma

2-Undifferentiated carcinoma with glandular component

Disease: 16.2: Esophagus and Esophagogastric Junction: Adenocarcinoma

9-Undifferentiated carcinoma, NOS

Disease: 16.1: Esophagus and Esophagogastric Junction: Squamous Cell
Carcinoma

BLANK-Histology is NOT 8020, Discriminator is not necessary

Esophagus (including GE junction) Squamous

Primary Site: C150-C155, C158-C159

Histology: 8050-8054, 8070, 8074, 8077, 8083, 8560

Primary Site: C160

Histology: 8050-8054, 8070, 8074, 8077, 8083, 8560

Primary Site: C150-C155, C158-C159

Histology: 8020

Primary Site: C160

Histology: 8020

Schema Discriminator 1: When primary site code is C160, the cancer will be staged using either the stomach cancer schema or the esophagus schema depending on the distance of the tumor's epicenter into the proximal stomach and whether or not the esophagogastric junction is involved.

Assign the code that best reflects EGJ involvement and the distance of the tumor's epicenter into the proximal stomach.

0-No involvement of esophagus or gastroesophageal junction AND epicenter at any distance into the proximal stomach (including distance unknown)

Disease: 17: Stomach

2-Involvement of esophagus or esophagogastric junction (EGJ) AND epicenter less than or equal to 2 cm into the proximal stomach

Disease: 16 Esophagus AND go to Schema Discriminator 2: Histology

Discriminator for 8020/3

3- Involvement of esophagus or esophagogastric junction (EGJ) AND epicenter greater than 2 cm into the proximal stomach

Disease: 17: Stomach

9-Unknown involvement of esophagus or gastroesophageal junction AND epicenter at any distance into the proximal stomach (including distance unknown)

Disease: 17: Stomach

BLANK-Primary Site is NOT C160, Discriminator is not necessary

Schema Discriminator 2: A schema discriminator is used to discriminate for histology

8020/3: Undifferentiated carcinoma to determine which Stage Group table to use.

1-Undifferentiated carcinoma with squamous component

Disease: 16.1: Esophagus and Esophagogastric Junction: Squamous Cell Carcinoma

2-Undifferentiated carcinoma with glandular component

Disease: 16.2: Esophagus and Esophagogastric Junction: Adenocarcinoma

9-Undifferentiated carcinoma, NOS

Disease: 16.1: Esophagus and Esophagogastric Junction: Squamous Cell Carcinoma

BLANK-Histology is NOT 8020, Discriminator is not necessary

Esophagus and EGJ, Squamous Cell (including adenosquamous), Tumor Location

0-U: Upper (Cervical/Proximal esophagus to lower border of azygos vein)

1-M: Middle (Lower border of azygos vein to lower border of inferior pulmonary vein)

2-L: Lower (Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction)

9-X: Esophagus, NOS, Specific location of epicenter not documented in medical record, Specific location of epicenter not assessed or unknown if assessed

Eye Other

Primary Site: C691-C694, C696, C698-C699

Histology: 8000-8700, 9700-9701

Primary Site: C691-C692, C695-C696, C698-C699

Histology: 8720-8790

Fallopian Tube

Primary Site: C570

Histology: 8000-8700, 8720-8790, 8806, 8810, 8815, 8822, 8825, 8890, 8930-8931, 8933, 8935-8936, 8950, 8960, 8980, 9000, 9050, 9052, 9060, 9070-9071, 9073, 9080, 9085, 9090-9091, 9100, 9110, 9700-9701

CA-125 (Carbohydrate Antigen 125) Pretreatment Interpretation

0-Negative/normal; within normal limits

1-Positive/elevated

2-Stated as borderline; undetermined whether positive or negative

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case, (If this item is required by your standard setter, use of code 8 will result in an edit error)

9-Not documented in medical record, CA-125 not assessed or unknown if assessed

Floor of Mouth

Primary Site: C040-C041, C048-C049

Histology: 8000-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Gallbladder

Primary Site: C230

Histology: 8000-8700, 8720-8790, 9700-9701

Genital Female Other

Primary: C577-C579

Histology: 8000-8700, 8720-8790, 9700-9701

Genital Male Other

Primary Site: C630-C631, C637-C639

Histology: 8000-8700, 8720-8790, 9700-9701

Primary Site: C632

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700

Gastrointestinal Stromal Tumors (GIST)

Primary Site: C000-C539, C571-C699, C739-C750, C754-

Histology: (any behavior) 8935-8936

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3) 8935-8936

Schema Discriminator 1: Since both omental and peritoneal gastrointestinal stromal tumors (GIST) are coded with the same ICD-O-3 topography code (C481), this data item must be used to identify the appropriate AJCC stage table.

1-Mesentery, Mesoappendix, Mesocolon, Pelvic peritoneum, Rectouterine pouch-Cul de sac-Pouch of Douglas, Other specified peritoneal site

Disease: Small Intestinal, Esophageal, Colorectal, Mesenteric and Peritoneal GIST

2-Omentum

Disease: Gastric and Omental GIST

9 Unknown or no information, Not documented in patient record

Disease: Small Intestinal, Esophageal, Colorectal, Mesenteric and Peritoneal GIST

BLANK-Primary Site is NOT C481, Discriminator is not necessary

KIT Gene Immunohistochemistry (IHC)

0-KIT negative/normal; within normal limits

1-KIT positive

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case, (If this information is required by your standard setter, use of code 8 may result in an edit error.)

9-Not documented in medical record, Cannot be determined by pathologist, KIT not assessed or unknown if assessed

Gum

Primary Site: C030, C031, C039, C062

Histology: 8000-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Heart, Mediastinum and Pleura

Primary Site: C380-C383, C388

Histology: 8000-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030, 9040-9043, 9045-9137, 9141-9230, 9240-9580, 9582, 9700-9701

Primary Site: C384

Histology: 8000-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030, 9040-9043, 9045, 9054-9137, 9141-9230, 9240-9580, 9582, 9700-9701

HemeRetic

Primary Site: C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809

Histology: 9591

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3{Malignant}) 9591

Primary Site: C000-C699, C739-C750, C754-C809

Histology: 9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3{Malignant}) 9724, 9727, 9740-9742, 9762-9809, 9811-9820, 9831-9920, 9931-9992

Primary Site: C000-C699, C739-C750, C754-C809

Histology: 9751, 9755-9759

Primary Site: C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809

Histology: 9930

Primary Site: C700-C729, C751-C75 3

Histology: (Behavior 3{Malignant}) 9930

Schema Discriminator 1: A schema discriminator is used to discriminate for histology 9591/3: Non-Hodgkin lymphoma to determine which Stage Group table to use.

1-Splenic B-cell lymphoma/leukemia, unclassifiable

Disease: 83: Leukemia

2-Hairy cell leukemia variant, Polymorphocytic variant of hairy cell leukemia

Disease: 83: Leukemia

3-Splenic diffuse red pulp small B-cell lymphoma, Splenic marginal zone lymphoma, diffuse variant, Splenic red pulp lymphoma with numerous basophilic villous lymphocytes, Splenic lymphoma with villous lymphocytes

Disease: 79.0: Lymphoma

9-Non-Hodgkin lymphoma, NOS, Any other terminology describing non-Hodgkin lymphoma, NOS

Disease: 79.0: Lymphoma

BLANK-Histology is NOT 9591, Discriminator is not necessary

Hypopharynx

Primary Site: C129, C130-C132, C138-C139

Histology: 8000-8700, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

III-Defined Other

Primary Site: C420-C424, C761-C765, C767-C768, C770-C775, C778-C779

Histology: 8000-8700, 8720-8790, 9700-9701

Primary Site: C760

Histology: 8000-8700, 8720-8790, 9700-9701

Primary Site: C809

Histology: 8000-8180, 8191-8246, 8248-8700, 8720-8790, 9700-9701

Schema Discriminator 1: This schema discriminator is used to discriminate between head and neck tumors with unknown primary site coded as C760. Some situations require that a more specific primary site be assigned.

0-Not Occult

Disease: EOD/SS schema (Ill-Defined, Other; Soft Tissue Other for 8941)

1-Occult, Negative cervical nodes (regional head and neck nodes)

Disease: EOD/SS schema (Ill-Defined, Other; Soft Tissue Other for 8941)

2-Not tested for EBV or p16 in head and neck regional nodes (EBV and p16 both unknown)

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

3-Unknown EBV, p16 negative in head and neck regional nodes

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

4-Unknown p16, EBV negative in head and neck regional nodes

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

5-Negative for both EBV and p16 in head and neck regional nodes

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

BLANK-Not C760, discriminator does not apply, Positive p16 in head and neck regional nodes, EBV unknown or negative, Assign primary site C109, Positive EBV in head and neck regional nodes, p16 positive, negative, or unknown, Assign primary site C119

Disease: Various, 10: HPV-Mediated (p16+) Oropharyngeal Cancer (C109), (Schema ID 00100: Oropharynx HPV-Mediated (p16+)), 9: Nasopharynx (C119)
Schema ID 00090: Nasopharynx)

Intracranial Gland

Primary Site: C751, C752, C753

Histology: (any behavior) 8000-8700, 8720-8790, 8900, 9064, 9070-9071, 9080, 9084-9085, 9100, 9120, 9140, 9220, 9362, 9380-9539, 9680, 9699, 9700-9714, 9751-9759

Primary Site: C751, C752, C753

Histology: (Behavior 0 {Benign} or Behavior 1 {Uncertain}) 8710-8714, 8800-8898, 8901-9063, 9065, 9072-9073, 9081-9083, 9086-9091, 9101-9110, 9121-9137, 9141-9210, 9221-9361, 9363-9373, 9540-9582

Primary Site: C751, C752, C753

Histology: (Behavior 0 {Benign} or Behavior 1 {Uncertain}) 9590-9679, 9687-9698, 9716-9742, 9761-9992

Kaposi Sarcoma

Primary Site: C000-C699, C739-C750, C754-C809

Histology: 9140

Kidney Parenchyma

Primary Site: C649

Histology: 8000-8700, 8720-8790, 9700-9701

Kidney Renal Pelvis

Primary Site: C659, C669

Histology: 8000-8700, 8720-8790, 9700-9701

Lacrimal Gland

Primary Site: C695

Histology: 8000-8700, 8941, 8980, 8982, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate between lacrimal gland and lacrimal sac tumors with primary site code C695: Lacrimal Gland. Code the site in which the tumor arose.

1-Lacrimal gland

Disease: 69: Lacrimal Gland Carcinoma

2-Lacrimal sac, Lacrimal duct NOS Nasal lacrimal duct/sac, Nasolacrimal duct

Disease: N/A: Lacrimal Sac (not TNM Staged)

9-Lacrimal, NOS

Disease: N/A: Lacrimal Sac (not TNM Staged)

Lacrimal Sac

Primary Site: C695

Histology: 8000-8700, 8941, 8980, 8982, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate between lacrimal gland and lacrimal sac tumors with primary site code C695: Lacrimal Gland. Code the site in which the tumor arose.

1-Lacrimal gland

Disease: 69: Lacrimal Gland Carcinoma

2-Lacrimal sac, Lacrimal duct NOS Nasal lacrimal duct/sac, Nasolacrimal duct

Disease: N/A: Lacrimal Sac (not TNM Staged)

9-Lacrimal, NOS

Disease: N/A: Lacrimal Sac (not TNM Staged)

Larynx Glottic

Primary Site: C320

Histology: 8000-8700, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Larynx Other

Primary Site: C323, C328-C329

Histology: 8000-8700, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Larynx Subglottic

Primary Site: C322

Histology: 8000-8700, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Larynx Supraglottic

Primary Site: C101, C321

Histology: 8000-8700, 9700-9701

Extranodal Extension Head and Neck Pathological

- 0.0-Lymph nodes positive for cancer but ENE not identified or negative
- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Lip

Primary Site: C003-C005, C008, C009

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Liver

Primary Site: C220

Histology: 8000-8700, 8720-8790, 9700-9701

AFP (Alpha Fetoprotein) Pretreatment Interpretation

- 0-Negative/normal; within normal limits
- 1-Positive/elevated
- 2-Borderline; undetermined if positive or negative
- 7-Test ordered, results not in chart
- 8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.)
- 9-Not documented in medical record, AFP pretreatment interpretation not assessed or unknown if assessed

Lung

Primary Site: C340-C343, C348-C349

Histology: 8000-8700, 8720-8790, 8972, 8980, 9700-9701

Lymphoma (excluding CLL/SLL)

Primary Site: C000-C424, C470-C509, C511-C608, C619-C631, C637-C689, C691-C694, C698-C699, C739-C749, C760-C809

Histology: 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738

Primary Site: C440, C442-C449, C510, C609, C632

Histology: 9590, 9596, 9650-9663, 9673-9679, 9687-9699, 9702-9705, 9714-9717, 9725, 9735, 9737-9738

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3 {Malignant}) 9590, 9596-9663, 9673-9679, 9687-9698, 9716-9719, 9725-9726, 9735, 9737-9738

Primary Site: C750, C754-C759

Histology: 9590, 9596-9663, 9673-9679, 9687-9698, 9716-9719, 9725-9726, 9735, 9737-9738

Primary Site: C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809

Histology: 9591

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3 {Malignant}) 9591

Primary Site: C750, C754-C759

Histology: 9680, 9699, 9702-9714

Primary Site: C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809

Histology: 9826-9827

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3 {Malignant}) 9826-9827

Schema Discriminator 1: A schema discriminator is used to discriminate for histology 9591/3: Non-Hodgkin lymphoma to determine which Stage Group table to use.

1-Splenic B-cell lymphoma/leukemia, unclassifiable

Disease: 83: Leukemia

2-Hairy cell leukemia variant, Prolymphocytic variant of hairy cell leukemia

Disease: 83: Leukemia

3-Splenic diffuse red pulp small B-cell lymphoma, Splenic marginal zone lymphoma, diffuse variant, Splenic red pulp lymphoma with numerous basophilic villous lymphocytes, Splenic lymphoma with villous lymphocytes

Disease: 79.0: Lymphoma

9-Non-Hodgkin lymphoma, NOS, Any other terminology describing non-Hodgkin lymphoma, NOS

Disease: 79.0: Lymphoma

BLANK-Histology is NOT 9591, Discriminator is not necessary

B Symptoms

0-No B symptoms (asymptomatic), Classified as "A" by physician when asymptomatic

1-Any B symptom(s), Night sweats (drenching), Unexplained fever (above 38 degrees C), Unexplained weight loss (generally greater than 10% of body weight in the six months before admission), B symptoms, NOS, Classified as "B" by physician when symptomatic

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, B symptoms not assessed or unknown if assessed

Lymphoma Ocular Adnexa

Primary Site: C441, C690, C695-C696

Histology: 9590-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930

Lymphoma-Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Primary Site: C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809

Histology: 9823

Primary Site: C700-C729, C751-C753

Histology: Behavior 3 {Malignant} 9823

B Symptoms

0-No B symptoms (asymptomatic), Classified as "A" by physician when asymptomatic

1-Any B symptom(s), Night sweats (drenching), Unexplained fever (above 38 degrees C), Unexplained weight loss (generally greater than 10% of body weight in the six months before admission), B symptoms, NOS, Classified as "B" by physician when symptomatic

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, B symptoms not assessed or unknown if assessed

Adenopathy

- 0-Adenopathy not identified/not present, No lymph nodes > 1.5 cm
- 1-Adenopathy present, Presence of lymph nodes > 1.5 cm
- 9-Not documented in medical record, Adenopathy not assessed or unknown if assessed

Organomegaly

- 0-Organomegaly of liver and/or spleen not present
- 1-Organomegaly of liver and/or spleen present
- 9-Not documented in medical record, Organomegaly not assessed or unknown if assessed

Anemia

- 0-Anemia not present, Hgb \geq 11.0 g/dL
- 1-Anemia present, Hgb <11.0 g/dL
- 6-Lab value unknown, physician states patient is anemic
- 7-Test ordered, results not in chart
- 9-Not documented in medical record, Anemia not assessed or unknown if assessed

Lymphocytosis

- 0-Lymphocytosis not present, Absolute lymphocyte count \leq 5,000 cells/ μ L
- 1-Lymphocytosis present, Absolute lymphocyte count > 5,000 cells/ μ L
- 6-Lab value unknown, physician states lymphocytosis is present
- 7-Test ordered, results not in chart
- 9-Not documented in medical record, Lymphocytosis not assessed or unknown if assessed

Thrombocytopenia

- 0-Thrombocytopenia not present, Platelets (Plt) \geq 100,000/ μ L
- 1-Thrombocytopenia present, Platelets (Plt) < 100,000/ μ L
- 6-Lab value unknown, physician states thrombocytopenia is present
- 7-Test ordered, results not in chart
- 9-Not documented in medical record, Thrombocytopenia not assessed or unknown if assessed

Major Salivary Glands

Primary Site: C079, C080-C081, C088-C089

Histology: 8000-8700, 8720-8790, 8941, 8974, 8980, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

- 0.0-Lymph nodes positive for cancer but ENE not identified or negative
- 0.1-9.9-ENE 0.1 to 9.9 mm

- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case, (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Maxillary Sinus

Primary Site: C310

Histology: 8000-8700, 8941, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

- 0.0-Lymph nodes positive for cancer but ENE not identified or negative
- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Melanoma Choroid and Ciliary Body

Primary Site: C693

Histology: 8720-8790

Primary Site: C694

Histology: 8720-8790

Schema Discriminator 1: A schema discriminator is used to discriminate between melanoma tumors with primary site code C694: Ciliary Body/Iris. Code the site in which the tumor arose.

1-Ciliary Body, Crystalline lens, Sclera, Uveal tract, Intraocular, Eyeball

Disease: 67:2 Uvea: Choroidal and Ciliary Body Melanomas

2-Iris

Disease: 67.1: Uveal Melanoma - Iris

BLANK-Primary Site is NOT C694, Discriminator is not necessary

Measured Thickness

0.0-No mass/tumor found

0.1-99.9-0.1 - 99.9 millimeters (mm), (Exact measurement to nearest tenth of mm)

XX.0-100 millimeters (mm) or larger

XX.1-Described as "less than 3 mm"

XX.2-Described as "at least" 3 mm

XX.3-Described as "at least" 6 mm

XX.4-Described as "at least" 9 mm

XX.5-Described as "at least" 12 mm

XX.6-Described as "greater than" 15 mm

XX.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code XX.8 may result in an edit error.)

XX.9-Not documented in medical record, Cannot be determined, Measured Thickness not assessed or unknown if assessed

Measured Basal Diameter

0.0-No mass/tumor found

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact measurement to nearest tenth of mm)

XX.0-100 millimeters (mm) or larger

XX.1-Described as "less than 3 mm"

XX.2-Described as "at least" 3 mm

XX.3-Described as "at least" 6 mm

XX.4-Described as "at least" 9 mm

XX.5-Described as "at least" 12 mm

XX.6-Described as "at least" 15 mm

XX.7-Described as "at least" 18 mm

XX.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code XX.8 may result in an edit error.)

XX.9-Not documented in medical record, Cannot be determined by pathologist, Measured Basal Diameter not assessed or unknown if assessed

Melanoma Conjunctiva

Primary Site: C690

Histology: 8720-8790

Malignant Melanoma of Head and Neck

Primary Site: C003-C005, C008-C009, C019, C020-C024, C028-C029, C030-C031, C039, C040-C041, C048-C049, C050-C052, C058-C059, C060-C062, C068-C069, C090-C091, C098-C099, C100-C104, C108-C109, C110-C113, C118-C119, C129, C130-C132, C138-C139, C140, C142, C148, C300-C313, C318-C319, C320-C323, C328-C329

Histology: 8720-8790

Extranodal Extension Head and Neck Pathological

- 0.0-Lymph nodes positive for cancer but ENE not identified or negative
- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Malignant Melanoma of Iris (excluding Ciliary Body)

Primary Site: C694

Histology: 8720-8790

Schema Discriminator 1: A schema discriminator is used to discriminate between melanoma tumors with primary site code C694: Ciliary Body/Iris. Code the site in which the tumor arose.

1-Ciliary Body, Crystalline lens, Sclera, Uveal tract, Intraocular, Eyeball

Disease: 67:2 Uvea: Choroidal and Ciliary Body Melanomas

2-Iris

Disease: 67.1: Uveal Melanoma - Iris

BLANK-Primary Site is NOT C694, Discriminator is not necessary

Melanoma Skin

Primary Site: C000-C002, C006, C440-C449, C500, C510-C512, C518-C519, C600-C602, C608-C609, C632

Histology: 8720-8790

Breslow Tumor Thickness

0.0-No mass/tumor found

0.1-Greater than 0.0 and less than or equal to 0.1

0.2-99.9-0.2 - 99.9 millimeters

XX.1-100 millimeters or larger

A0.1-A9.9-Stated as "at least" some measured value of 0.1 to 9.9

AX.0-Stated as greater than 9.9 mm

XX.8-Not applicable: Information not collected for this schema (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Microinvasion; microscopic focus or foci only and no depth given, Cannot be determined by pathologist, In situ melanoma, Breslow Tumor Thickness not assessed or unknown if assessed

Ulceration

0-Ulceration not identified/not present

1-Ulceration present

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error.)

9-Not documented in medical record, Cannot be determined by the pathologist
Pathology report does not mention ulceration, Ulceration not assessed or unknown if assessed

Mitotic Rate Melanoma

00-0 mitoses per square millimeter (mm), Mitoses absent, No mitoses present

01-99-1 - 99 mitoses/square mm

(Exact measurement in mitoses/square mm)

X1-100 mitoses/square mm or more

X2-Stated as "less than 1 mitosis/square mm", Stated as "nonmitogenic"

X3-Stated as "at least 1 mitosis/square mm", Stated as "mitogenic"

X4-Mitotic rate described with denominator other than square millimeter (mm)

X7-Test ordered, results not in chart

X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)

X9-Not documented in medical record, Mitotic Rate Melanoma not assessed or unknown if assessed

LDH (Lactate Dehydrogenase) Pretreatment Level

0-Normal LDH level, Low, below normal

1-Above normal LDH level; High

7-Test ordered, results not in chart

9-Not documented in medical record, LDH (Lactate Dehydrogenase) Pretreatment Level not assessed or unknown if assessed

Merkel Cell Skin

Primary Site: C000-C006, C008-C009, C440-C449, C510-C512, C518-C519, C600-C602, C608-C609, C632

Histology: 8041, 8190, 8247

Primary Site: C809

Histology: 8190, 8247

Middle Ear

Primary Site: C301

Histology: 8000-8700, 9700-9701

Mouth Other

Primary Site: C058-C059, C068-C069

Histology: 8000-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Mycosis Fungoides

Primary Site: C000-C002, C006, C440-C449, C510-C512, C518-C519, C600-C602, C608-C609, C632

Histology: 9700-9701

Peripheral Blood Involvement

- 0-Absence of significant blood involvement, 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells, Clone unknown, Stated as B0
B Map=B0
- 1-Absence of significant blood involvement, 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells, Clone negative, Stated as B0a
B Map=B0a

2-Absence of significant blood involvement, 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells, Clone positive, Stated as B0b

B Map=B0b

3-Low blood tumor burden, More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2, Clone unknown, Stated as B1

B Map=B1

4-Low blood tumor burden, More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2, Clone negative, Stated as B1a

B Map=B1a

5-Low blood tumor burden, More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2, Clone positive, Stated as B1b

B Map=B1b

6-High blood tumor burden, Greater than or equal to 1000 Sezary cells per microliter (uL), Clone positive, Stated as B2

B Map=B2

7-Test ordered, results not in chart

B Map=BX

9-Not documented in medical record, Peripheral Blood Involvement not assessed or unknown if assessed

B Map=BX

<BLANK> Death Certificate Only, no value provided

B Map=BX

Nasal Cavity and Ethmoid Sinus

Primary Site: C300, C311

Histology: 8000-8700, 8941, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Nasopharynx

Primary Site: C110, C112-C113, C118-C119

Histology: 8000-8700, 9700-9701

Primary Site: C111

Histology: 8000-8700, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate for primary site C111: Posterior wall of nasopharynx. Code the specific site in which the tumor arose.

1-Posterior wall of nasopharynx, NOS

Disease: 9: Nasopharynx

2-Adenoid, Pharyngeal tonsil

Disease: Schema discriminator 2: Oropharyngeal p16

BLANK-Primary Site is NOT C111, Discriminator is not necessary

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Neuroendocrine Tumor (NET) Adrenal Gland

Primary Site: C740, C741, C749, C755

Histology: 8680, 8690, 8692-8693, 8700

Neuroendocrine Tumor (NET) Ampulla of Vater

Primary Site: C241

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Neuroendocrine Tumor (NET) Appendix

Primary Site: C181

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Neuroendocrine Tumor (NET) Colon and Rectum

Primary Site: C180, C182-C189, C199, C209

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Neuroendocrine Tumor (NET) Duodenum

Primary Site: C170

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Neuroendocrine Tumor (NET) Jejunum and Ileum

Primary Site: C171-C173, C178-C179

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Neuroendocrine Tumor (NET) Pancreas

Primary Site: C250-C254, C257-C259

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Neuroendocrine Tumor (NET) Stomach

Primary Site: C160-C166, C168-C169

Histology: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683

Orbital Sarcoma

Primary Site: C690-C694, C696, C698-C699

Histology: 8710-8714, 8800-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9137, 9141-9175, 9181-9230, 9240-9509, 9520-9582

Primary Site: C695

Histology: 8710-8714, 8800-8921, 8932-8934, 8940, 8950-8975, 8981, 8983-8990, 9000-9016, 9030-9137, 9141-9175, 9181-9230, 9240-9509, 9520-9582

Primary Site: C723

Histology: (Behavior 3 {Malignant}) 8710-8714, 8800-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9063, 9065, 9071-9073, 9081-9083, 9086-9091, 9101-9137, 9141-9175, 9181-9230, 9240-9361, 9363-9373, 9421, 9473, 9500, 9522, 9530, 9540-9582

Oropharynx (p16-)

Primary Site: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109

Histology: 8000-8700, 9700-9701

Primary Site: C111

Histology: 8000-8700, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate for primary site C111: Posterior wall of nasopharynx. Code the specific site in which the tumor arose.

1-Posterior wall of nasopharynx, NOS

Disease: 9: Nasopharynx

2-Adenoid, Pharyngeal tonsil

Disease: Schema discriminator 2: Oropharyngeal p16

BLANK-Primary Site is NOT C111, Discriminator is not necessary

Schema Discriminator 2: A schema discriminator is used to discriminate between oropharyngeal tumors that are p16 positive and oropharyngeal tumors that are p16 negative OR p16 status unknown.

1-p16 Negative; Nonreactive

Disease: 11.1: Oropharynx (p16-)

2-p16 Positive; HPV Positive; Diffuse, Strong reactivity

Disease: 10: HPV-Mediated (p16+) Oropharyngeal Cancer

9-Not tested for p16; Unknown

Disease: 11.1: Oropharynx (p16-)

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Oropharynx HPV-Mediated (p16+)

Primary Site: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109

Histology: 8000-8700, 9700-9701

Primary Site: C111

Histology: 8000-8700, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate for primary site C111: Posterior wall of nasopharynx. Code the specific site in which the tumor arose.

1-Posterior wall of nasopharynx, NOS

Disease: 9: Nasopharynx

2-Adenoid, Pharyngeal tonsil

Disease: Schema discriminator 2: Oropharyngeal p16

BLANK-Primary Site is NOT C111, Discriminator is not necessary

Schema Discriminator 2: A schema discriminator is used to discriminate between oropharyngeal tumors that are p16 positive and oropharyngeal tumors that are p16 negative OR p16 status unknown.

1-p16 Negative; Nonreactive

Disease: 11.1: Oropharynx (p16-)

2-p16 Positive; HPV Positive; Diffuse, Strong reactivity

Disease: 10: HPV-Mediated (p16+) Oropharyngeal Cancer

9-Not tested for p16; Unknown

Disease: 11.1: Oropharynx (p16-)

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

- 0.1-9.9-ENE 0.1 to 9.9 mm
- X.1-ENE 10 mm or greater
- X.2-ENE microscopic, size unknown, Stated as ENE (mi)
- X.3-ENE major, size unknown, Stated as ENE (ma)
- X.4-ENE present, microscopic or major unknown, size unknown
- X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
- X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
- X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

- 0.0-No involved regional nodes
- 0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1-100 millimeters (mm) or greater
- XX.2-Microscopic focus or foci only and no size of focus given
- XX.3-Described as "less than 1 centimeter (cm)"
- XX.4-Described as "at least" 2 cm
- XX.5-Described as "at least" 3 cm
- XX.6-Described as "at least" 4 cm
- XX.7-Described as greater than 5 cm
- XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
- XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Ovary

Primary Site: C569

Histology: 8000-8700, 8720-8790, 8806, 8810, 8815, 8822, 8825, 8890, 8930-8931, 8933, 8935-8936, 8950, 8960, 8980, 9000, 9050, 9052, 9060, 9070-9071, 9073, 9080, 9085, 9090-9091, 9100, 9110, 9700-9701

CA-125 (Carbohydrate Antigen 125) Pretreatment Interpretation

- 0-Negative/normal; within normal limits
- 1-Positive/elevated
- 2-Stated as borderline; undetermined whether positive or negative
- 7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error)
9-Not documented in medical record, CA-125 not assessed or unknown if assessed

Palate Hard

Primary Site: C050

Histology: 8000-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative
0.1-9.9-ENE 0.1 to 9.9 mm
X.1-ENE 10 mm or greater
X.2-ENE microscopic, size unknown, Stated as ENE (mi)
X.3-ENE major, size unknown, Stated as ENE (ma)
X.4-ENE present, microscopic or major unknown, size unknown
X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)
X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)
X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes
0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
XX.1-100 millimeters (mm) or greater
XX.2-Microscopic focus or foci only and no size of focus given
XX.3-Described as "less than 1 centimeter (cm)"
XX.4-Described as "at least" 2 cm
XX.5-Described as "at least" 3 cm
XX.6-Described as "at least" 4 cm
XX.7-Described as greater than 5 cm
XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)
XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Pancreas

Primary Site: C250-C254, C257-C259

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 8971, 9700-9701

Parathyroid

Primary Site: C750

Histology: 8000-8700, 8720-8790, 9700-9701

Penis

Primary Site: C600-C602, C608-C609

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700

Pharynx Other

Primary Site: C140, C142, C148

Histology: 8000-8700, 9700-9701

Placenta

Primary Site: C589

Histology: 8000-8700, 8720-8790, 9100-9105, 9700-9701

Gestational Trophoblastic Prognostic Scoring Index

00-25-Risk factor score

X9-Not documented in medical record, Prognostic scoring index not assessed, or unknown if assessed

Plasma Cell Disorders

Primary Site: C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809

Histology: 9671, 9734

Primary Site: C000-C699, C739-C750, C754-C809

Histology: 9731, 9761

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3 {Malignant}) 9671, 9731, 9734, 9761

Plasma Cell Myeloma

Primary Site: C000-C699, C739-C750, C754-C809

Histology: 9732

Primary Site: C700-C729, C751-C753

Histology: (Behavior 3 {Malignant}) 9732

Schema Discriminator 1: Multiple Myeloma Terminology

0-Multiple myeloma, Myeloma, NOS, Non-secretory myeloma, Plasma cell myeloma (PCM), Ultra-High-Risk Smoldering MM (SMM)

Staging: RISS Stage

1-Smoldering plasma cell myeloma (SPCM), Asymptomatic plasma cell myeloma, Early myeloma, Evolving myeloma

Staging: No RISS Stage

9-Other terminology describing myeloma, Unknown terminology used

Staging: No RISS Stage

High Risk Cytogenetics

0-High-risk cytogenetics not identified/not present

1-High-risk cytogenetics present

7-Test ordered, results not in chart

9-Not documented in medical record, High Risk Cytogenetics not assessed or unknown if assessed

Serum Albumin Pretreatment Level

0-Serum albumin <3.5 g/dL

1-Serum albumin ≥3.5 g/dL

7-Test ordered, results not in chart

9-Not documented in medical record, Serum Albumin not assessed or unknown if assessed

Serum Beta-2 Microglobulin Pretreatment Level

0-β2-microglobulin < 3.5 mg/L

1-β2-microglobulin ≥ 3.5 mg/L < 5.5 mg/L

2-β2-microglobulin ≥ 5.5 mg/L

7-Test ordered, results not in chart

9-Not documented in medical record, Serum Beta-2 Microglobulin Pretreatment, Level not assessed or unknown if assessed

LDH (Lactate Dehydrogenase) Pretreatment Level

0-Normal LDH level, Low, below normal

1-Above normal LDH level; High

7-Test ordered, results not in chart

9-Not documented in medical record, LDH (Lactate Dehydrogenase)

Pretreatment Level not assessed or unknown if assessed

Pleural Mesothelioma

Primary Site: C340-C349, C384

Histology: 9050-9053

Primary Cutaneous Lymphoma (excluding MF and SS)

Primary Site: C440, C442-C449, C510, C609, C632

Histology: 9597, 9680, 9708-9709, 9712, 9718-9719, 9726

Primary Peritoneal Carcinoma

Primary Site: (Female) C481, C482, C488

Histology: 8000-8700, 8720-8790, 8806, 8822, 8930-8931, 8933, 8950, 8960, 8980, 9000, 9050, 9052, 9060, 9070-9071, 9073, 9080, 9085, 9090-9091, 9100, 9110, 9700-9701

CA-125 (Carbohydrate Antigen 125) Pretreatment Interpretation

0-Negative/normal; within normal limits

1-Positive/elevated

2-Stated as borderline; undetermined whether positive or negative

7-Test ordered, results not in chart

8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error)

9-Not documented in medical record, CA-125 not assessed or unknown if assessed

Prostate

Primary Site: C619

Histology: 8000-8700, 8720-8790, 9700-9701

PSA (Prostatic Specific Antigen) Lab Value

0.1-0.1 or less nanograms/milliliter (ng/ml) (Exact value to nearest tenth of ng/ml)

0.2-999.9-0.2 - 999.9 ng/ml (Exact value to nearest tenth of ng/ml)

XXX.1-1,000 ng/ml or greater

XXX.7-Test ordered, results not in chart

XXX.9-Not documented in medical record, PSA lab value not assessed or unknown if assessed

Number of Cores Positive

00-All examined cores negative

01-99-1 - 99 cores positive (Exact number of cores positive)

X1-100 or more cores positive

X6-Biopsy cores positive, number unknown

X7-No needle core biopsy performed

X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)

X9-Not documented in medical record, Number of cores positive not assessed or unknown if assessed

Number of Cores Examined

01-99-1 - 99 cores examined (Exact number of cores examined)

X1-100 or more cores examined

X6-Biopsy cores examined, number unknown

X7-No needle core biopsy performed

X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)

X9-Not documented in medical record, Number of cores examined not assessed or unknown if assessed

Gleason Score Clinical

02-Gleason score 2

03-Gleason score 3

04-Gleason score 4

05-Gleason score 5

06-Gleason score 6

07-Gleason score 7

08-Gleason score 8

09-Gleason score 9

10-Gleason score 10

X7-No needle core biopsy/TURP performed

X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)

X9-Not documented in medical record, Gleason Score Clinical not assessed or unknown if assessed

Gleason Patterns Clinical

- 11-Primary pattern 1, secondary pattern 1
- 12-Primary pattern 1, secondary pattern 2
- 13-Primary pattern 1, secondary pattern 3
- 14-Primary pattern 1, secondary pattern 4
- 15-Primary pattern 1, secondary pattern 5
- 19-Primary pattern 1, secondary pattern unknown
- 21-Primary pattern 2, secondary pattern 1
- 22-Primary pattern 2, secondary pattern 2
- 23-Primary pattern 2, secondary pattern 3
- 24-Primary pattern 2, secondary pattern 4
- 25-Primary pattern 2, secondary pattern 5
- 29-Primary pattern 2, secondary pattern unknown
- 31-Primary pattern 3, secondary pattern 1
- 32-Primary pattern 3, secondary pattern 2
- 33-Primary pattern 3, secondary pattern 3
- 34-Primary pattern 3, secondary pattern 4
- 35-Primary pattern 3, secondary pattern 5
- 39-Primary pattern 3, secondary pattern unknown
- 41-Primary pattern 4, secondary pattern 1
- 42-Primary pattern 4, secondary pattern 2
- 43-Primary pattern 4, secondary pattern 3
- 44-Primary pattern 4, secondary pattern 4
- 45-Primary pattern 4, secondary pattern 5
- 49-Primary pattern 4, secondary pattern unknown
- 51-Primary pattern 5, secondary pattern 1
- 52-Primary pattern 5, secondary pattern 2
- 53-Primary pattern 5, secondary pattern 3
- 54-Primary pattern 5, secondary pattern 4
- 55-Primary pattern 5, secondary pattern 5
- 59-Primary pattern 5, secondary pattern unknown
- X6-Primary pattern unknown, secondary pattern unknown
- X7-No needle core biopsy/TURP performed
- X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)
- X9-Not documented in medical record, Gleason Patterns Clinical not assessed or unknown if assessed

Gleason Score Pathological

02-Gleason score 2

03-Gleason score 3

04-Gleason score 4

05-Gleason score 5

06-Gleason score 6

07-Gleason score 7

08-Gleason score 8

09-Gleason score 9

10-Gleason score 10

X7-No prostatectomy done

X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)

X9-Not documented in medical record, Gleason Score Pathological not assessed or unknown if assessed

Gleason Patterns Pathological

11-Primary pattern 1, secondary pattern 1

12-Primary pattern 1, secondary pattern 2

13-Primary pattern 1, secondary pattern 3

14-Primary pattern 1, secondary pattern 4

15-Primary pattern 1, secondary pattern 5

19-Primary pattern 1, secondary pattern unknown

21-Primary pattern 2, secondary pattern 1

22-Primary pattern 2, secondary pattern 2

23-Primary pattern 2, secondary pattern 3

24-Primary pattern 2, secondary pattern 4

25-Primary pattern 2, secondary pattern 5

29-Primary pattern 2, secondary pattern unknown

31-Primary pattern 3, secondary pattern 1

32-Primary pattern 3, secondary pattern 2

33-Primary pattern 3, secondary pattern 3

34-Primary pattern 3, secondary pattern 4

35-Primary pattern 3, secondary pattern 5

39-Primary pattern 3, secondary pattern unknown

41-Primary pattern 4, secondary pattern 1

42-Primary pattern 4, secondary pattern 2

43-Primary pattern 4, secondary pattern 3

44-Primary pattern 4, secondary pattern 4

45-Primary pattern 4, secondary pattern 5
49-Primary pattern 4, secondary pattern unknown
51-Primary pattern 5, secondary pattern 1
52-Primary pattern 5, secondary pattern 2
53-Primary pattern 5, secondary pattern 3
54-Primary pattern 5, secondary pattern 4
55-Primary pattern 5, secondary pattern 5
59-Primary pattern 5, secondary pattern unknown
X6-Primary pattern unknown, secondary pattern unknown
X7-No needle core biopsy/TURP performed
X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)
X9-Not documented in medical record, Gleason Patterns Clinical not assessed or unknown if assessed

Gleason Tertiary Pattern

10-Tertiary pattern 1
20-Tertiary pattern 2
30-Tertiary pattern 3
40-Tertiary pattern 4
50-Tertiary pattern 5
X7-No prostatectomy/autopsy performed
X8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error.)
X9-Not documented in medical record, Gleason Tertiary Pattern not assessed or unknown if assessed

Respiratory Other

Primary Site: C390, C398-C399

Histology: 8000-8700, 8720-8790, 9700-9701

Retinoblastoma

Primary Site: C690-C696, C698-C699

Histology: 9510-9514

Heritable Trait

0-H0: Normal RB1 alleles, No clinical evidence of mutation
1-H1: RB1 gene mutation OR Clinical evidence of mutation
7-Test ordered, results not in chart

9-HX: Not documented in medical record, Test not done, or unknown if done,
Insufficient evidence of a constitutional RB1 gene mutation

Retroperitoneum

Primary Site: C480

Histology: 8000-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582, 9700-9701

Primary Site: C481-C482, C488 (Sex=male, other, transsexual, transsexual-natal male and not stated/unknown)

Histology: 8000-8700, 8720-8790, 8822, 8933, 8950, 8960, 8980, 9000, 9050, 9052, 9060, 9070-9071, 9073, 9080, 9085, 9090-9091, 9100, 9110, 9700-9701

Primary Site: C481-C482, C488

Histology: 8710-8714, 8800-8803, 8810-8821, 8823-8921, 8932, 8934, 8940-8941, 8951-8959, 8963-8975, 8981-8990, 9010-9016, 9030-9043, 9045, 9051, 9053-9055, 9061-9065, 9072, 9081-9084, 9086, 9101-9105, 9120-9137, 9141-9230, 9240-9580, 9582

Sinus Other

Primary Site: C312-C313, C318-C319

Histology: 8000-8700, 9700-9701

Skin Eyelid

Primary Site: C441

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700, 8940-8941, 8980

Skin Other

Primary Site: C445-C449

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700, 8940, 8982

Small Intestine

Primary Site: C170-C173, C178-C179

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 9700-9701

Soft Tissue Abdomen and Thoracic (excluding Heart, Mediastinum and Pleura)

Primary Site: C151-C152, C154-C155, C159, C160-C220, C239-C249, C260-C269, C339, C379, C600-C619, C630-C689

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582

Primary Site: C221

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8975, 8981-8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582

Primary Site: C250-C259

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8970, 8972-8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582

Primary Site: C340-C349

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8971, 8973-8975, 8981-8990, 9000-9016, 9030-9043, 9045, 9054-9137, 9141-9230, 9240-9580, 9582

Primary Site: C473-C475, C493-C495

Histology: 8000-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582, 9700-9701

Primary Site: C510-C519

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9070, 9072-9137, 9141-9230, 9240-9580, 9582

Primary Site: C529

Histology: 8710-8714, 8800-8803, 8810-8921, 8932, 8934, 8940-8975, 8981-8990, 9000-9016, 9030-9043, 9045-9070, 9072-9105, 9120-9137, 9141-9230, 9240-9580, 9582

Primary Site: C530-C539

Histology: 8710-8714, 8800-8803, 8810-8921, 8932, 8934, 8940-8975, 8981-8990, 9000-9016, 9030-9043, 9045-9105, 9120-9137, 9141-9230, 9240-9580, 9582

Primary Site: C589

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9091, 9110-9137, 9141-9230, 9240-9580, 9582

Primary Site: C620-C629

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9060, 9062-9063, 9072-9073, 9082-9083, 9086-9091, 9102-9103, 9110-9137, 9141-9230, 9240-9580, 9582

Soft Tissue Head and Neck

Primary Site: C000-C002, C006

Histology: (any behavior) 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8941-8981, 8983-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582

Primary Site: C003-C005, C008-C009, C020-C023, C028-C050, C058-C069

Histology: (any behavior) 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8981, 8983-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582

Primary Site: C019, C024, C051-C052, C090-C148, C150, C153, C158, C301, C312-C329, C739, C750, C754-C759

Histology: (any behavior) 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582

Primary Site: C079-C089

Histology: (any behavior) 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940, 8950-8973, 8975, 8981, 8983-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582

Primary Site: C300, C310-C311

Histology: (any behavior) 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8940, 8950-8981, 8983-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582

Primary Site: C470, C490

Histology: (any behavior) 8000-8803, 8810-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9110, 9121-9137, 9141-9230, 9240-9580, 9582, 9700-9701

Primary Site: C722, C724-C725, C751-C753

Histology: (Behavior 3{Malignant}) 8710-8714, 8800-8803, 8810-8898, 8901-8905, 8912, 8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9063, 9065, 9072-9073, 9081-9083, 9086-9091, 9101-9110, 9121-9137, 9141-9210, 9221-9230, 9240-9361, 9363-9373, 9540-9580, 9582

Soft Tissue Other

Primary Site: C000-C148, C150, C153, C158, C300-C329, C470, C490, C739, C750, C754-C759
Histology: (any behavior) 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581

Primary Site: C151-C152, C154-C155, C159, C160-C269, C339-C388, C471-C479, C491-C499, C500-C509, C529, C589-C689
Histology: (any behavior) 8804-8806, 8930-8931, 8991, 9020, 9044, 9231, 9581

Primary Site: C390, C398-C399, C420-C424
Histology: (any behavior) 8710-8714, 8800-8934, 8940-9137, 9141-9582

Primary Site: C440, C442-C449
Histology: (any behavior) 8710-8714, 8800-8934, 8941-8981, 8983-9137, 9141-9582

Primary Site: C441
Histology: (any behavior) 8710-8714, 8800-8934, 8950-8975, 8981-9137, 9141-9582

Primary Site: C480-C488
Histology: (any behavior) 8804-8805, 8991, 9020, 9044, 9231, 9581

Primary Site: C480
Histology: (any behavior) 8806, 8930-8931

Primary Site: C481-C482, C488 (Sex=male, other, transsexual, transsexual-natal male and not stated/unknown)
Histology: (any behavior) 8806, 8930-8931

Primary Site: C510-C519
Histology: (any behavior) 8804-8806, 8930-8931, 8991, 9044, 9231, 9581

Primary Site: C530-C539
Histology: (any behavior) 8804, 8806, 8930-8931, 8991, 9020, 9044, 9231

Primary Site: C569, C570
Histology: (any behavior) 8710-8714, 8800-8805, 8811-8814, 8820-8821, 8823-8824, 8826-8881, 8891-8921, 8932, 8934, 8940-8941, 8951-8959, 8963-8975, 8981-8991, 9010-9045, 9051, 9053-9055, 9061-9065, 9072, 9081-9084, 9086, 9101-9105, 9120-9137, 9141-9582

Primary Site: C571-C579

Histology: (any behavior) 8710-8714, 8800-8934, 8940-9137, 9141-9582

Primary Site: C690-C696, C698-C699

Histology: (any behavior) 8930-8931, 8991, 9020, 9180, 9231

Primary Site: C700-C721, C728-C729

Histology: (Behavior 3{Malignant}) 8710-8714, 8800-8801, 8803-8806, 8811-8814, 8820-8842, 8851-8881, 8891-8898, 8901-8934, 8940-9063, 9065, 9072-9073, 9081-9083, 9086-9091, 9110, 9121-9132, 9135-9137, 9141-9175, 9181-9210, 9221-9361, 9363, 9365-9373, 9541-9582

Primary Site: C722, C724-C725, C751-C753

Histology: (Behavior 3{Malignant}) 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9231, 9581

Primary Site: C723

Histology: (Behavior 3{Malignant}) 8930-8931, 8991, 9020, 9231

Primary Site: C740-C749, C761-C765, C767-C768, C770-C775, C778-C779, C809

Histology: (any behavior) 8710-8714, 8800-8934, 8940-9137, 9141-9582

Primary Site: C760

Histology: (any behavior) 8710-8714, 8800-8934, 8940, 8950-9137, 9141-9582

Primary Site: C760

Histology: (any behavior) 8941

Schema Discriminator 1: This schema discriminator is used to discriminate between head and neck tumors with unknown primary site coded as C760. Some situations require that a more specific primary site be assigned.

0-Not Occult

Disease: EOD/SS schema (III-Defined, Other; Soft Tissue Other for 8941)

1-Occult, Negative cervical nodes (regional head and neck nodes)

Disease: EOD/SS schema (III-Defined, Other; Soft Tissue Other for 8941)

2-Not tested for EBV or p16 in head and neck regional nodes (EBV and p16 both unknown)

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

3-Unknown EBV, p16 negative in head and neck regional nodes

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

4-Unknown p16, EBV negative in head and neck regional nodes

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

5-Negative for both EBV and p16 in head and neck regional nodes

Disease: 6: Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

BLANK-Not C760, discriminator does not apply, Positive p16 in head and neck regional nodes, EBV unknown or negative, Assign primary site C109, Positive EBV in head and neck regional nodes, p16 positive, negative, or unknown, Assign primary site C119

Disease: Various, 10: HPV-Mediated (p16+) Oropharyngeal Cancer (C109), (Schema ID 00100: Oropharynx HPV-Mediated (p16+)), 9: Nasopharynx (C119) Schema ID 00090: Nasopharynx)

Soft Tissue Trunk and Extremities

Primary Site: C471-C472, C476, C478-C479, C491-C492, C496, C498-C499

Histology: 8000-8803, 8810-8921, 8932-8934, 8940-8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582, 9700-9701

Primary Site: C500-C506, C508-C509

Histology: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8981, 8990, 9000-9016, 9030-9043, 9045-9137, 9141-9230, 9240-9580, 9582

Stomach

Primary Site: C160

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 9700-9701

Primary Site: C161-C166, C168-C169

Histology: 8000-8149, 8154, 8157, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 9700-9701

Schema Discriminator 1: When primary site code is C160, the cancer will be staged using either the stomach cancer schema or the esophagus schema depending on the distance of the tumor's epicenter into the proximal stomach and whether or not the esophagogastric junction is involved.

Assign the code that best reflects EGJ involvement and the distance of the tumor's epicenter into the proximal stomach.

0-No involvement of esophagus or gastroesophageal junction AND epicenter at any distance into the proximal stomach (including distance unknown)

Disease: 17: Stomach

2-Involvement of esophagus or esophagogastric junction (EGJ) AND epicenter less than or equal to 2 cm into the proximal stomach

Disease: 16 Esophagus AND go to Schema Discriminator 2: Histology
Discriminator for 8020/3

3- Involvement of esophagus or esophagogastric junction (EGJ) AND epicenter greater than 2 cm into the proximal stomach

Disease: 17: Stomach

9-Unknown involvement of esophagus or gastroesophageal junction AND epicenter at any distance into the proximal stomach (including distance unknown)

Disease: 17: Stomach

BLANK-Primary Site is NOT C160, Discriminator is not necessary

Testis

Primary Site: C620-C621, C629

Histology: 8000-8700, 8720-8790, 9061, 9064-9065, 9070-9071, 9080-9081, 9084-9085, 9100-9101, 9104-9105, 9700-9701

Testis Serum Markers (S) Clinical (pre orchiectomy)

0-S0: Marker study levels within normal levels

1-S1: At least one of these values is elevated AND - LDH less than 1.5 x N* AND - hCG (mIU/L) less than 5,000 AND - AFP (ng/mL) less than 1,000

2-S2: LDH 1.5 x N* to 10 x N* OR - hCG (mIU/L) 5,000 to 50,000 OR - AFP (ng/mL) 1,000 to 10,000

3-S3: Only one elevated test is needed - LDH greater than 10 x N* OR - hCG (mIU/mL) greater than 50,000 OR - AFP (ng/mL) greater than 10,000

9-SX: Not documented in medical record, S-Category Clinical not assessed or unknown if assessed

Testis Serum Markers (S) Pathological (post-orchiectomy)

0-S0: Marker study levels within normal levels

1-S1: At least one of these values is elevated AND - LDH less than 1.5 x N* AND - hCG (mIU/L) less than 5,000 AND - AFP (ng/mL) less than 1,000
2-S2: LDH 1.5 x N* to 10 x N* OR - hCG (mIU/L) 5,000 to 50,000 OR - AFP (ng/mL) 1,000 to 10,000
3-S3: Only one elevated test is needed - LDH greater than 10 x N* OR - hCG (mIU/mL) greater than 50,000 OR - AFP (ng/mL) greater than 10,000
9-SX: Not documented in medical record, S-Category Clinical not assessed or unknown if assessed

Thymus

Primary Site: C379

Histology: 8000-8700, 8720-8790, 9700-9701

Thyroid

Primary Site: C739

Histology: 8000-8344, 8350-8420, 8440-8509, 8514-8700, 8720-8790, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate between thyroid gland and thyroglossal duct tumors with primary site code C739: Thyroid Gland. Code the site in which the tumor arose.

1-Thyroid gland, Thyroid NOS

Disease: Eligible for AJCC staging - 73.1: Thyroid: Differentiated, - 73.2: Thyroid: Anaplastic, - 74: Thyroid: Medullary

2-Thyroglossal duct cyst

Disease: NOT eligible for AJCC staging

Thyroid Medullary

Primary Site: C739

Histology: 8345-8347, 8430, 8510, 8512-8513

Schema Discriminator 1: A schema discriminator is used to discriminate between thyroid gland and thyroglossal duct tumors with primary site code C739: Thyroid Gland. Code the site in which the tumor arose.

1-Thyroid gland, Thyroid NOS

Disease: Eligible for AJCC staging - 73.1: Thyroid: Differentiated, - 73.2: Thyroid: Anaplastic, - 74: Thyroid: Medullary

2-Thyroglossal duct cyst

Disease: NOT eligible for AJCC staging

Tongue Anterior

Primary Site: C020-C023, C028-C029

Histology: 8000-8700, 8982, 9700-9701

Extranodal Extension Head and Neck Pathological

0.0-Lymph nodes positive for cancer but ENE not identified or negative

0.1-9.9-ENE 0.1 to 9.9 mm

X.1-ENE 10 mm or greater

X.2-ENE microscopic, size unknown, Stated as ENE (mi)

X.3-ENE major, size unknown, Stated as ENE (ma)

X.4-ENE present, microscopic or major unknown, size unknown

X.7-Surgically resected regional lymph node(s) negative for cancer (pN0)

X.8-Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X.8 may result in an edit error)

X.9-Not documented in medical record, No surgical resection of regional lymph node(s), ENE not assessed pathologically, or unknown if assessed, Pathological assessment of lymph node(s) not done, or unknown if done

Lymph Nodes Size of Mets

0.0-No involved regional nodes

0.1-99.9-0.1 - 99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)

XX.1-100 millimeters (mm) or greater

XX.2-Microscopic focus or foci only and no size of focus given

XX.3-Described as "less than 1 centimeter (cm)"

XX.4-Described as "at least" 2 cm

XX.5-Described as "at least" 3 cm

XX.6-Described as "at least" 4 cm

XX.7-Described as greater than 5 cm

XX.8-Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XX.8 will result in an edit error)

XX.9-Not documented in medical record, Regional lymph node(s) involved, size not stated, Lymph Nodes Size not assessed, or unknown if assessed

Trachea

Primary Site: C339

Histology: 8000-8700, 8720-8790, 9700-9701

Urethra

Primary Site: C680

Histology: 8000-8700, 8720-8790, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate between urethra (male and female) and prostatic urethra. Code the site in which the tumor arose.

1-Male Penile Urethra, Female Urethra, Urethral Gland, Cowper gland, Urethra, NOS

Disease: 63.1 Male Penile and Female Urethra: Urothelial Carcinomas; 63.2 Male Penile and Female Urethra: Squamous Cell Carcinoma and Adenocarcinoma

2 Males only, - Prostatic urethra, - Prostatic utricle

Disease: 63.3 Prostatic Urethra: Urothelial Carcinomas; 63.4 Prostatic Urethra: Squamous Cell Carcinoma and Adenocarcinoma

Urethra-Prostatic

Primary Site: C680

Histology: 8000-8700, 8720-8790, 9700-9701

Schema Discriminator 1: A schema discriminator is used to discriminate between urethra (male and female) and prostatic urethra. Code the site in which the tumor arose.

1-Male Penile Urethra, Female Urethra, Urethral Gland, Cowper gland, Urethra, NOS

Disease: 63.1 Male Penile and Female Urethra: Urothelial Carcinomas; 63.2 Male Penile and Female Urethra: Squamous Cell Carcinoma and Adenocarcinoma

2 Males only, - Prostatic urethra, - Prostatic utricle

Disease: 63.3 Prostatic Urethra: Urothelial Carcinomas; 63.4 Prostatic Urethra: Squamous Cell Carcinoma and Adenocarcinoma

Urinary Other

Primary Site: C681, C688-C689

Histology: 8000-8700, 8720-8790, 9700-9701

Vagina

Primary Site: C529

Histology: 8000-8700, 8720-8790, 8933, 8980, 9071, 9110, 9700-9701

Vulva

Primary Site: C510-C512, C518-C519

Histology: 8000-8040, 8042-8180, 8191-8246, 8248-8700, 9020, 9071